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INTRODUCTION 
Antibiotics, the compounds which inhibit microbial growth or kill them, were 
once thought as wonder drugs closing the book of infectious diseases. 
Nevertheless, soon after the widespread use of antibiotics clinically relevant 
resistant strains appeared, and they started to spread worldwide. At first, the 
discovery rate of new drugs was high, and the resistant bacteria were not that 
big of a problem as there were plenty of new drugs or even families of drugs 
coming into clinical use. As time went by, less and less new drugs were 
identified or developed leading to the situation that there was a period of 30 
years where only one entirely new family of antibiotics reached the market 
(Butler and Buss, 2006). As the list of effective drugs is getting scarcer and new 
drugs are emerging rarely, more interest has been paid to the strategies how to 
increase efficiency of the existing drugs. 
As various physiological processes are involved in responses to antibiotics 
and, as antibiotics have broad impact on bacterial physiology, one strategy to 
potentiate existing drugs is to co-inhibit some other processes leading to higher 
sensitivity to the drugs. One such target is tmRNA that is conducting process 
called trans-translation, which releases ribosomes stalled on mRNAs (Vioque & 
de la Cruz, 2003, de la Cruz & Vioque, 2001, Abo et al., 2002). The first part of 
the current thesis is concentrating on the closer examination of antibiotic 
sensitivity of tmRNA deficient strain of Escherichia coli. 
Bacterial populations contain a small subpopulation of cells insensitive to 
most of the antibiotics. Those cells are called persisters, and they are thought to 
be responsible for chronic and long-term infections (Lewis, 2010). Eradicating 
those cells would help to make treatments with current drugs more effective. 
Unfortunately, the essence of persister cells is not clear, although they are 
known over 60 years. Therefore, the second part of the experimental section of 
my thesis is dedicated to describing this intriguing phenomenon in more detail. 
Particularly, I have been interested to find out how the age of the inoculum is 
affecting the frequency of persisters in the model organism E. coli. 
3
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1. REVIEW OF LITERATURE 
1.1. Definition of antibiotics 
Introduction to antibiotics should start with definition of antibiotics, but it is not 
as straightforward as it seems, because there are multiple definitions of 
antibiotics. Most common definition for antibiotics is that they are compounds 
that are killing microorganism or slowing down their growth at low concentra-
tions (in other words in high dilution). Sometimes only antibacterial agents are 
counted as antibiotics excluding, for example, antifungal agents. Some 
definitions, on the other hand, include only compounds produced by micro-
organisms and exclude synthetic compounds as does the first definition by 
Selman Waksman (Waksman, 1947). Nowadays the discrimination by the 
origin is not well reasoned since many antibiotics used are semisynthetic and 
total synthesis for many natural antibiotics is possible (Tatsuta, 2008) or is even 
in practical use (for example, chloramphenicol (Sinhg, 2002)). 
 
 
1.2. Classification of antibiotics 
Antibiotics can be classified in different ways. Most commonly it is done by 
their chemical structure forming structural classes like macrolides, amino-
glycosides, β-lactams etc. Mechanism of action or target is another way to 
classify antibiotics. Main targets for most common antibiotics are DNA, RNA, 
protein and cell wall synthesis, structure and function of cell membrane and 
folic acid synthesis. Components of biosynthetic machinery differ to some 
extent between eukaryotes and prokaryotes, which are making human and 
animal use of antibiotics, targeting previously mentioned processes, possible.  
Antibiotics that belong to the same structural class mostly have the same 
target and mechanism of action. Aminoglycosides make an interesting 
exception, as they target protein synthesis in different ways. The most common 
aminoglycosides are causing translational misreading (Gromadski & Rodnina, 
2004, Carter et al., 2000). An unique member of aminoglycosides is 
kasugamycin, which inhibits initiation of translation and is bacteriostatic, while 
the other members of the class are bactericidal (Pestka, 1979). 
 
1.2.1. Bactericidal and bacteriostatic antibiotics 
Another way to classify antibiotics is to divide them, according to their ability 
to cause cell death or hamper the growth, into groups of bactericidal and 
bacteriostatic drugs. Although definitions of those terms seem to be 
straightforward and simple, the situation is actually quite complicated. Anti-
biotics that are bactericidal against one class of organisms do not often kill 
another type of bacteria.  
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Multiple definitions can be found in the literature for the bactericidal or 
bacteriostatic activity. Microbiological in vitro definition can be based on 
changes of the viability counts – in case of decrease of CFUs the drug is called 
bactericidal. Authors with more clinical background are often using definition 
based on more quantitative estimate and use a parameter called minimal 
bactericidal concentration (MBC). MBC is defined as the lowest concentration 
of the compound causing death of 99,9% bacteria during 18–24 hours of 
incubation (Amsterdam, 2005). This means that an antibiotic is called 
bactericidal, when it can cause CFU drop of at least three orders of magnitude. 
Antibiotics that are able to kill only 90% or 99% of the cells do not qualify as 
bactericidal by this rather strict definition. Some tolerant strains might not die 
fast enough complicating the use of this definition. This is probably the reason 
why sometimes lower killing yields are used for defining bactericidal activity 
(Lamb et al., 1999). 
Minimal inhibitory concentration (MIC), the lowest concentration of the 
compound that is inhibiting visible growth of microorganisms during 18–24 
hours of incubation (Wiegand et al., 2008), is another parameter used for 
defining the type of antibiotic activity. Particularly, MBC/MIC ratio is used for 
this type of estimation – bacteriostatic are antibiotics with MBC/MIC > 4 
(Pankey and Sabath, 2004). Often antibiotics, classically considered being 
bactericidal, have MBC and MIC ratio around one (Smith, 2004). 
However, the determination of MBC to MIC ratio can be problematic since 
the techniques of measuring those parameters have not always been 
standardized and some varying technical parameters can influence the outcome 
(Pankey and Sabath, 2004). To summarize, the definition of bactericidal or 
bacteriostatic activity of an agent can be applied to certain organism (or even 
strain) in certain testing conditions. 
Characterizing antibiotics by bactericidal or bacteriostatic activity in a 
clinical practice takes into account in vivo effects of the drug. Those may not 
overlap with the in vitro results, since the pharmacodynamic/pharmacokinetic 
parameters are influencing the outcome. There are several cases where 
antibiotics having in vitro bactericidal activity can act in vivo only bacterio-
statically (Menashe et al., 2008) and also vice versa (Zurenko et al., 2001). 
One example of drugs with complex behavior is macrolides that are 
considered to be bacteriostatic; however, the situation is not so simple. Most of 
the macrolides are actually concentration dependently bactericidal, although the 
concentrations needed for killing in vitro are usually much higher than 
achievable in human plasma, meaning that in clinical use they are mostly still 
bacteriostatic (Zhanel et al., 2001). More potent is the ketolide subfamily with 
the so far only marketed member telithromycin having MIC and MBC values 
often much lower compared to other macrolides, so that the plasma 
concentration is exceeding MIC or even MBC and the drug is bactericidal also 
in vivo (Muller-Serieys et al., 2004, Drago et al., 2005). 
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Beside the concentration of the drug, also the type of pathogen can influence 
the mode of activity of macrolides, meaning that the list of organisms killed 
effectively depends on the drug. For example, erythromycin is in vitro 
bactericidal against Streptococcus pneumoniae and Streptococcus pyogenes, 
while clarithromycin and azithromycin are bactericidal against S. pyogenes and 
Haemophilus influenzae and the ketolides are bactericidal against S. pneumo-
niae and H. influenzae (Zhanel et al., 2001, Kanatani & Guglielmo, 1994). 
Another interesting fact about macrolides is that azithromycin and 
clarithromycin are effective against several pathogens (for example, against H. 
influenzae), although their serum concentrations do not reach the MIC value 
(Zhanel et al., 2001). This is due to the absorption of the drug at high levels to 
some tissues and fluids; in addition, azithromycin does concentrate into the 
white blood cells which might transport the drugs to the site of infection 
(Zhanel et al., 2001, Schentag & Ballow, 1991, Rodvold et al., 1997). 
Pseudomonas aeruginosa is also an example of microbe having much higher 
in vitro MIC values (measured using exponential phase cultures) than the 
achievable concentration in infection site (Zhanel et al., 2001, Mulet et al., 
2009). However, macrolides, especially azithromycin, are actively used for the 
treatment of chronic P. aeruginosa infections in cystic fibrosis (CF) patients. 
This is remarkable, because in the airways of the CF patients P. aeruginosa 
forms microcolonies or biofilms, i.e., formations where cells are usually less 
susceptible to antibiotics compared to planktonic cells. It is revealed now that 
azithromycin is more active (even bactericidal) against biofilm (Mulet et al., 
2009) or stationary phase culture (Imamura et al., 2005) compared to the 
exponential phase cells. There are indications that azithromycin is directly 
disrupting outer membrane of the stationary phase cells (Imamura et al., 2005), 
although the killing is strictly protein synthesis dependent (Kohler et al., 2007, 
Klepser et al., 1997, Klepser et al., 1996, Athamna et al., 2004). It suggests that 
the disruption of the outer membrane will result in increased uptake of 
azithromycin, which will lead to the stronger inhibition of protein synthesis and 
thereafter to the death of the cells. 
In addition to macrolides, there are many other antibiotics that can act in 
some cases as bactericidal and in others as bacteriostatic. Clindamycin is a 
representative of lincosamide subclass of antibiotics that are considered to be 
bacteriostatic, but this drug has been shown to have in vitro bactericidal activity 
against some organisms (Klepser et al., 1997, Klepser et al., 1996, Athamna et 
al., 2004). This is the case also for linezolid (representative of oxazolidiniones) 
(Zurenko et al., 2001). Chloramphenicol that is considered to be a classical 
bacteriostatic antibiotic can also be bactericidal against some organisms (Rahal 
and Simberkoff, 1979). Interestingly, stationary phase cells of H. influenzae are 
more sensitive to chloramphenicol as compared to exponential phase culture 
(Feldman and Manning, 1983), although an opposite effect is observed with 
most organisms and drugs. 
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Chloramphenicol is bacteriostatic against most of the E. coli strains having 
MBC values 250 μg/ml or more (Rahal and Simberkoff, 1979). This is about an 
order of magnitude higher than concentrations regularly used in vitro 
(Sambrook et al., 1989), not to mention achievable plasma concentrations 
(Kohanski et al., 2010). Still there are E. coli K-1 strains with MBC values 
much lower (10–80 μg/ml) and comparable with the achievable plasma 
concentrations. The reason of this decrease in MBC value is unknown, but it 
might involve the specific polysaccharide capsule of these strains (Orskov et al., 
1977). This is supported by the observation that chloramphenicol also is 
bactericidal against several other bacteria causing meningitis (Robbins et al., 
1974, Rahal & Simberkoff, 1979), which also have capsules that can be very 
similar if not identical to E. coli K-1 (for example, N. meningitis group B) 
(Echarti et al., 1983). In addition, it is possible that adaptations needed for 
causing meningitis are somehow involved with bactericidal activity of 
chloramphenicol. 
The inhibitor of RNA synthesis, rifampicin, is considered bactericidal 
against Gram-positive bacteria but bacteriostatic against Gram-negative bacteria 
(Kohanski et al., 2010). Interestingly, recA mutant of E. coli is killed by 
rifampicin, yet the mechanism behind it is unknown (Kohanski et al., 2007). 
Dividing antibiotics by their ability to kill or not to kill bacteria raises the 
question which of the classes should be preferred for clinical use. Actually, the 
debate over clinical preference of bactericidal or bacteriostatic antibiotics has 
been going for years, and there are only some cases when clinical experiences 
and animal models are favoring bactericidal drugs (Pankey and Sabath, 2004). 
Still, there are some disadvantages of killing or specially lysing bacteria, mostly 
involving release of bacterial products. For example, endo- and exotoxins may 
be released, which can stimulate production of cytokines, which leads to 
harmful inflammations or even toxic shock syndrome (Pankey & Sabath, 2004, 
Finberg et al., 2004). 
 
1.2.2. Broad and narrow spectrum antibiotics 
Antibiotics are divided also into a broad spectrum or narrow spectrum anti-
biotics depending on the variety of organisms they affect. The broad spectrum 
antibiotics (for example, tetracyclines and newer β-lactams) usually are potent 
against both Gram-positive and Gram-negative bacteria. The narrow spectrum 
antibiotics (for example, older penicillins and macrolides) affect only smaller 
group of bacteria (Acar, 1997). The difference between those antibiotic groups 
comes probably mostly from the cell penetration ability (for example, the outer 
membrane of Gram-negative bacteria can be an efficient barrier for several 
drugs) or low conservation of the target. 
 
 
 
4
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1.3. Effects of antibiotic combinations 
Another interesting aspect about impact of antibiotics on bacteria is their effects 
when acting in combinations. Multidrug treatments are important in clinical use, 
mostly to provide broad-spectrum coverage to patients who are seriously ill and 
may be septicemic. In addition, multidrug combinations are used to enhance the 
treatment efficiency and to avoid the development of resistance; good example 
is tuberculosis treatment, where combination of four drugs is used (Hecht, 
2005). Combining drugs is also an interesting tool for studying biological 
systems and interactions between different cellular processes (Tsui et al., 2004, 
Lehar et al., 2007, Lehar et al., 2008, Keith et al., 2005).  
Combinations of drugs can be classified as antagonistic, additive or 
synergistic depending on their combined effect being less, equal or greater than 
expected sum of their individual inhibitory effects. Reasons for such effects are 
not often clear and can be quite complex. 
The synergistic drug combinations are the one that have gained most of the 
attention due to the increased potency. The downside of these kinds of combi-
nations can be the increased risk in resistance development. The antagonistic 
drug combinations, on the contrary, can slow down or even reverse resistance 
(Yeh et al., 2006, Michel et al., 2008, Hegreness et al., 2008, Chait et al., 
2007). Still, those papers are theoretical or based on laboratory experiments and 
there are no clinical reports about this issue.  
Mechanisms for achieving the synergism can be various. For example, one 
drug can increase uptake of another. This is the case for cell wall synthesis 
inhibitors that are increasing uptake of aminoglycosides by causing changes in 
the cell wall (Moellering and Weinberg, 1971). Other ways of causing 
synergistic effects are observed when the additional drug is inhibiting resistance 
enzymes (for example, β-lactamases) (Walsh, 2003) or efflux pumps protecting 
bacteria from another drug (Pages and Amaral, 2009).  
Synergistic effects are often observed when combined antibiotics are inhi-
biting sequential reactions. One example of this kind of interactions is between 
trimethoprim and sulfonamides which are both inhibiting tetrahydrofolate 
synthesis (Walsh, 2003). The mechanism of how the synergistic outcome forms 
is not clear. Moreover, there are some doubts on theoretical grounds about the 
possibility of simple inhibition of sequential reactions to lead to synergistic 
effects (Webb, 1963). Recently, it has been shown that the synergy of 
trimethoprim and sulfonamides is much more complicated and probably 
involves differential inhibition of various downstream biosynthetic reactions 
(Nichols et al., 2011).  
Synergistic effects between the antibiotics inhibiting sequential reactions are 
also observed between classes of different cell wall syntheses inhibitors, for 
example, between penicillins and vancomycin or phosphomycin analogues 
(Pillai et al., 2005).  
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Another interesting synergistic interaction occurs between streptogramins, 
especially between the representatives of streptogramin A and B groups, which 
are produced by organisms usually in pair ways (Pestka, 1979; Walsh, 2003). 
Separately they are considered to be bacteriostatic agents, but this combination 
is in addition to higher potency also bactericidal (Lamb et al., 1999). Drugs of 
both classes are binding to the region of peptidyl transferase center (PTC). The 
representatives of class A are inhibiting peptidyl transferase reaction directly by 
interfering with substrate binding at both acceptor and donor sites of the PTC. 
Their binding is causing conformational changes in the ribosome, this way 
enhancing binding of the streptogramin B into the nascent peptide exiting tunnel 
(Harms et al., 2004), where it is inhibiting peptide chain elongation and is 
inducing detachment of incomplete peptide chains. Cooperatively the affinity of 
the drugs to the ribosome is very high and thereby leads to efficient blocking of 
protein synthesis.  
In addition to already mentioned synergistic interactions there are many 
more combinations where mechanism of antibiotic action is largely or totally 
unknown (Yeh et al., 2006, Pillai et al., 2005).  
Antagonistic interactions are also common between antibiotics but are 
mostly described in vitro. The reason for the underrepresentation of in vivo 
studies might come from the difficulties to recognize antagonism in case of 
complex diseases in the presence of intact immune system, which is actually 
playing very important role in the eradication of pathogens (Pillai et al., 2005). 
Antagonistic interactions have been often observed between bacteriostatic 
and bactericidal antibiotics. Examples involve bacteriostatic inhibitors of 
protein synthesis in combination with β-lactams or vancomycin. Those 
bactericidal antibiotics kill only growing cells but in the mentioned examples 
bacteriostatic drugs are causing stasis that is diminishing lethal activity of the 
killing drug. The antagonism between the bactericidal aminoglycosides and 
bacteriostatic inhibitors of protein synthesis is explained by possible inhibition 
of energy-dependent active uptake of aminoglycosides or just by inhibition of 
translation that has to be active for killing by aminoglycosides (Pillai et al., 
2005). 
Suppressive drug interaction is the extreme case of the antagonistic drug 
interactions when the combined inhibitory effect is not just smaller than the 
expected additive sum but even smaller than the effect of either drug alone 
(Pillai et al., 2005). This type of interactions occur between protein and DNA 
synthesis inhibitors. During DNA damage synthesis of DNA is down regulated 
in contrary to the production of ribosomes, which leads to the imbalance 
between DNA and protein content in cell. Addition of protein synthesis 
inhibitors can decrease the production of ribosomes and thereby restore the 
balance of proteins and DNA and therefore improve growth and survival of the 
bacteria (Bollenbach et al., 2009). 
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1.4. Antibiotic killing mechanisms 
Besides the inhibition of certain processes, the interaction between antibiotics 
and their targets can also have broader effects, which, among others, may lead 
to the killing of cells. The most studied drug-target interactions that are 
connected to cell death are inhibition of topoisomerases and cause of double 
stranded DNA breaks (Drlica et al., 2008), inhibition of synthesis and damaging 
of structural integrity of cell wall (Tomasz, 1979) and protein mistranslation 
(Magnet and Blanchard, 2005).  
 
1.4.1. DNA replication inhibitors 
Modulation of DNA supercoiling is essential for DNA synthesis, transcription 
and cell division and it is catalyzed by topoisomerases by breaking and 
rejoining the DNA strand. The topoisomerase II (DNA gyrase) is thought to be 
responsible for reducing supercoiling during replication. The topoisomerase IV 
at the same time is unlinking or decatenating chromatin, but it can also reduce 
the supercoiling (Espeli and Marians, 2004). Those reactions are targeted by the 
class of antibiotics called quinolones with clinically significant subclass of 
fluoroquinolones. Quinolones are targeting topoisomerase II and IV and thereby 
causing double stranded breaks to the DNA (Sugino et al., 1977, Gellert et al., 
1977, Drlica et al., 2008, Chen et al., 1996). Quinolone preferences to the 
topoisomerases are varying depending on the organism. In Gram-negative 
bacteria, the main target is the topoisomerase II, and in Gram-positive 
organisms the topoisomerase IV acts as primary target (Drlica and Zhao, 1997). 
The topoisomerases II and IV are heterodimeric enzymes, which work as a 
tetrameric complexs, where each dimeric enzyme is catalyzing formation of 
single-stranded break into one of the DNA strands and will stay covalently 
bound to the 5’ end of the DNA (Morrison et al., 1980, Mizuuchi et al., 1980). 
This complex will be stalled by the quinolones as the DNA religation is 
inhibited and the so-called cleaved complex is formed (Heddle et al., 2000). 
Subsequently, the replication will be stalled due to the collision of replication 
fork and the cleaved complex (Wentzell and Maxwell, 2000). 
The double-stranded breaks are reversible at the moderate (bacteriostatic) 
concentrations of the drug. It means that just the inhibition of the replication or 
the generation of breaks cannot be lethal per se. Still, slow killing has been 
observed at the low drug concentrations over longer time period, but it is 
mechanistically poorly understood (Drlica et al., 2008). 
At the higher antibiotic concentrations bacteria will be killed faster. At the 
same time, the double stranded breaks are not reversible anymore, implying that 
the cleaved complexes dissociate (Malik et al., 2006, Chen et al., 1996). As the 
cleaved complexes are scattered all around the chromosome, the widespread 
fragmentation of the chromosome will occur, and it could be the direct cause of 
fast death (Drlica et al., 2008). This hypothesis is supported by the observation 
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that when the quinolone mediated killing is blocked by the anaerobiosis or by 
the inhibition of translation with the chloramphenicol, the fragmentation of the 
chromosome is in correlation with cell death (Malik et al., 2006, Malik et al., 
2007). 
The killing mechanism by the quinolones seems to be more complex, and 
there are two separate mechanism suggested for the fast killing: protein 
synthesis-dependent and independent cell death (Drlica et al., 2008). It is known 
that the inhibition of the translation by the chloramphenicol can block or reduce 
the killing activity of some quinolones. For example, killing of E. coli by 
nalidixic acid is stopped completely (Malik et al., 2007, Crumplin & Smith, 
1975), although by norfloxacin only partially (Malik et al., 2006). At the same 
time, there are several newer compounds, still without conventional names, that 
are not blocked at all (Malik et al., 2006, Malik et al., 2007). This suggests that 
some antibiotics can induce both pathways. 
The complexity of the killing mechanism of quinolones was shown by 
finding that anaerobiosis can inhibit killing by some quinolones (Malik et al., 
2006, Malik et al., 2007). Later it was demonstrated that quinolones are 
inducing hydroxyl radicals via protein synthesis-dependent pathway, and this is 
needed for the killing activity (Dwyer et al., 2007). Preliminary results suggest 
that fragmentation of the chromosome is not depending on the formation of the 
hydroxyl radicals, meaning that fragmentation by itself cannot be the reason of 
death induced through this pathway (X. Wang, unpublished results). 
Induction of hydroxyl radical formation was observed also for quinolones 
that are thought to kill via the protein synthesis-independent pathway (Wang et 
al., 2010b). As protein synthesis has been claimed to be essential for hydroxyl 
radical formation (Dwyer et al., 2007), this suggests that, in case of these drugs, 
also the protein synthesis dependent killing pathway is induced but could be too 
slow to play significant role in cell death. At the same time, addition of 
chloramphenicol inhibited formation of hydroxyl radicals only slightly meaning 
that hydroxyl radicals could be formed also by protein synthesis independent 
pathway.  
 
1.4.2. Cell wall synthesis inhibitors 
Peptidoclycan is an important structural component of bacterial cell wall, which 
gives strength and stability to the cell and counteracts with osmotic pressure of 
the cytoplasm. There are many types of antibiotics that inhibit peptidoglycan 
production at different stages of its synthesis, and the main classes are β-lactams 
and glycopeptide antibiotics (Walsh, 2003). They block the crosslinking of the 
peptidoglycan units that are building blocks of the cell wall. β-lactams 
(penicillins, carbapenems, penems, monopenems and cephalosporins) bind to 
the transpeptidases while glycoprotein antibiotics bind to the peptidoglycan, 
both classes of drugs inhibit the same crosslinking reaction.  
5 
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The deadly mechanism of action of the cell wall inhibitors could be quite 
straitforward, as it was initially thought (Wise and Park, 1965). The idea is that 
during growth defective peptidoglycan will be produced, which results in 
weakened cell wall, that at some point does not bear the osmotic pressure and 
the cell will rupture. Later it was noted that penicillin can stop growth of some 
bacterial strains without causing lysis (Tomasz et al., 1970). This finding lead to 
the conclusion that the bacterial lysis was more complex and can included 
active degradation by autolysins (Tomasz, 1979, Moreillon et al., 1990, Kitano 
& Tomasz, 1979). At the same time, the mechanism of activation of the 
autolytic system remained unknown until the end of last century when several 
loci coding for proteins involved in activation of autolysins were described 
(Novak et al., 1999, Novak et al., 2000b, Brunskill & Bayles, 1996, Rice et al., 
2003, Groicher et al., 2000). Activation of two of the loci is dependent of 
proton motive force(Groicher et al., 2000, Rice et al., 2003). This suggests that 
the electrophysiological state of the membranes is involved in the autolytic 
activation. Still, the activation mechanisms of the autolytic pathways are poorly 
understood (Rice & Bayles, 2008, Mitchell & Tuomanen, 2002).  
In case of the autolysis-inhibiting agents or the autolysin defective strains, 
the non-autolytic cell death has been described (Novak et al., 2000b, Moreillon 
et al., 1990), although the mechanism is not clear. To make it more complicated 
there are some indications that SOS response might be involved in the β-lactam 
mediated cell death (Kohanski et al., 2010). Maybe the most interesting fact is 
that some β-lactams that are not very effective inducers of the lysis can cause 
the cell filamentation at lower concentrations (Spratt, 1975) similarly to the 
quinolones (Drlica et al., 2008). The filamentation could be caused by their 
ability to activate SOS response that might be a protective reaction as SOS 
deficient mutants have an increased susceptibility to these drugs (Miller et al., 
2004). 
 
1.4.3. Drugs inducing protein mistranslation 
There are very many classes of the antibiotics that inhibit translation by inter-
fering with a wide variety of steps of the protein synthesis. Among the large 
number of drug families, only the aminoglycosides are broadly bactericidal 
(Magnet and Blanchard, 2005), although the members of other classes of the 
inhibitors of the protein synthesis can be bactericidal at a concentration- or 
species-dependent manner (Zhanel et al., 2001, Schentag & Ballow, 1991, 
Rodvold et al., 1997, Rahal & Simberkoff, 1979, Muller-Serieys et al., 2004, 
Klepser et al., 1997, Kanatani & Guglielmo, 1994, Drago et al., 2005). 
Three large and well studied subfamilies of the aminoglycosides are 
neomycin, kanamycin and gentamycin families (Bryskier, 2005). These drugs 
have the same one main binding site on the ribosome. They bind to A site of the 
30S subunit specifically to helix 44 of 16S RNA (Yoshizawa et al., 1998, 
Vicens & Westhof, 2002, Carter et al., 2000). These aminoglycosides interact 
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with two universally conserved nucleotides A1492 and A1493. These 
nucleotides are important to recognize the correct codon-anticodon pairing. In 
case of the correct codon-anticodon base-pairing, the two nucleotides will be 
flipped out and will form hydrogen bonds with the minihelix that is formed 
between codon and anticodon regions. This way the affinity between the 
ribosome and the aminoacyl-tRNA will be increased, and the translation will 
continue at higher probability with this aminoacyl-tRNA. When the mentioned 
aminoglycosides are bound to the ribosome, the nucleotides A1492 and A1493 
are stabilized in flipped-out conformation. In case of wrong codon-anticodon 
pairing, it will result in increased affinity of the wrong aminoacyl-tRNA, and 
the translation with the “wrong” aminoacyl-tRNA will proceed with high 
probability. This will result in the incorporation of the incorrect amino acids and 
the formation of mistranslated proteins (Carter et al., 2000). 
Streptomycin, which is also bactericidal drug, is structurally a bit different as 
compared to the aminoglycoside subfamilies mentioned above (Bryskier, 2005). 
Streptomycin causes mistranslation, but it has slightly different binding site that 
is actually adjacent to the binding site of previously mentioned aminoglycosides 
(Carter et al., 2000). The mechanism how the miscoding is achieved differs 
from the neomycin, kanamycin and gentamycin subfamilies (Gromadski & 
Rodnina, 2004, Carter et al., 2000). Streptomycin causes larger conformational 
changes in the ribosome so that the non-cognate tRNA is stabilized and fidelity 
is influenced at the initial binding step of aminoacyl-tRNA as well at the proof-
reading step. 
While the mechanism of action of the aminoglycosides at the translational 
level is quite well established (Gromadski & Rodnina, 2004, Carter et al., 
2000), the origin of the bactericidal effect is not so clear. It is reported that the 
uptake of aminoglycosides into the cytoplasm requires membrane-potential and 
is important for the bactericidal activity (Bryan & Kwan, 1983, Arrow & Taber, 
1986). This explains why some anaerobes are less susceptible to the amino-
glycosides or facultative aerobes are not sensitive at anaerobic conditions 
(Kogut et al., 1965, Hancock, 1962). It is observed that protein synthesis also is 
necessary for the killing activity, as it leads to the increased uptake, which 
probably is a result of pore formation through the incorporation of mistranslated 
or truncated proteins into the membrane (Davis et al., 1986). The increased 
uptake of the drug is thought to be irreversible, and it leads to the permanently 
elevated intercellular concentration of the drug (Nichols and Young, 1985). It 
has been proposed that the following cell death is caused by complete inhibition 
of protein synthesis through the elevated drug concentration (Mehta & 
Champney, 2002, Magnet & Blanchard, 2005) or the disruption of the 
membrane integrity (Bryan and Kwan, 1983). It is also proposed that the 
aminoglycosides competitively displace Mg2+ and Ca2+ ions, which link 
adjacent lipopolysaccharides, which results in the formation of holes in the cell 
envelope (Stratton, 2005). Recently additional mechanisms have been proposed, 
as discussed below. 
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1.4.4. Common mechanism of killing through  
reactive oxygen species 
Recently a common mechanism involved in killing by different classes of 
antibiotics was described (Zabransky et al., 1973, Kohanski et al., 2008, 
Kohanski et al., 2007, Dwyer et al., 2007, Dwyer et al., 2009, Davies et al., 
2009) (Fig. 1). The end product of this mechanism was shown to be reactive 
hydroxyl radical capable of damaging DNA, lipids and proteins that could be 
the direct cause of the cell death (Imlay, 2003). This mechanism was shown to 
be operational for the fluoroquinolones, aminoglycosides and β-lactams 
(Kohanski et al., 2007), which are the most studied bactericidal antibiotics and 
have different primary drug-target interactions (Tomasz, 1979, Magnet & 
Blanchard, 2005, Drlica et al., 2008).  
The first common step toward the formation of hydroxyl radical is a 
production of superoxide (Dwyer et al., 2009). Superoxide is forming also from 
molecular oxygen through a respiratory electron transport chain also during 
homeostasis (Storz and Imlay, 1999) and is converted to hydrogen peroxide by 
superoxide dismutase. Subsequently, the hydrogen peroxide is in turn eradicated 
by catalases/peroxidises (Imlay, 2008). In case of antibiotic stress, the activity 
of the respiratory electron transport chain is increased so that the formation of 
superoxide is overwhelming cellular defense mechanisms (Dwyer et al., 2009).  
The increased activity of the electron transport chain included stimulated 
NADH reduction through tricarboxylic (TCA) cycle. It has been shown that by 
modulating TCA cycle ability to form NADH, by removing TCA cycle key 
enzymes, reduces killing efficacy of drugs in correlation with the potential 
NADH forming ability (Kohanski et al., 2007). 
An excess of superoxide can damage Fe-S clusters in proteins that leads to a 
formation of free ferrous iron (Fe2+) and could include also the unbalance in 
iron metabolism and regulation (Dwyer et al., 2007). Ferrous iron can catalyze 
the formation of hydroxyl radical through Fenton reaction (Imlay et al., 1988) 
that could lead to the already mentioned damage of DNA, lipids and proteins 
(Imlay, 2003).  
It has been suggested that the oxidative damage death pathway might be a 
maladaptive response originating from oxygen free past and is now exploited by 
bactericidal drugs and some DNA damaging toxins (Dwyer et al., 2007). 
Interestingly, it has been hypothesized that the apoptosis mechanisms in 
eukaryotes, which have several parallels with the radical mediated cell death in 
bacteria, might have evolved from the same maladaptive response (Dwyer et al., 
2007). 
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Figure 1. Common mechanism of cell death induced by bactericidal antibiotics 
(adapted from Kohanski et al., 2010). 
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The above-described common mechanism of the activation of the death 
pathway by various drugs is not very clear. The main question is how the TCA 
cycle and electron transport chain are activated? It has been described in some 
extent for the aminoglycosides (Kohanski et al., 2008). It has been shown that 
the incorporation of mistranslated and misfolded proteins into the membrane 
does induce the two-component stress response system CpxAR which activates 
the envelope stress response that is important for efficient killing. In addition, a 
redox responsive activity of another membrane associated two-component 
system ArcAB is crucial for the oxidative damage death pathway, and it is 
thought to activate the TCA cycle and respiration electron transport chain by an 
unknown mechanism. ArcAB is thought to be activated by CpxAR, but the 
exact way is waiting to be described. Interestingly, the disruption of those two-
component systems reduced the killing efficacy also by the quinolones and  
β-lactams showing the broader role of the redox-responsive and envelope stress-
responsive two-component systems in this pathway (Kohanski et al., 2008).  
The existence of common death pathway is also supported by the fact that 
the SOS response deficient strain is more sensitive to all three classes of the 
bactericidal antibiotics, emphasizing the role of DNA damage by hydroxyl 
radicals (Kohanski et al., 2007). In addition, it has been shown that β-lactams 
are capable to induce the SOS response (Miller et al., 2004) as well as 
quinolones that directly cause the DNA damage (Kelley, 2006). It is also 
noteworthy that the chaperon systems are activated by all bactericidal drugs 
tested, although only for the aminoglycosides the primary drug-target 
interaction could lead to the protein misfolding. This could indicate a possible 
hydroxyl radical mediated protein damage (Kohanski et al., 2007).  
It is important to note that the knock-out strains for all those mentioned key 
components are usually, at least in some extent, still sensitive to bactericidal 
antibiotics (Mitchell & Tuomanen, 2002, Kohanski et al., 2008, Kohanski et al., 
2007, Dwyer et al., 2007). Also, when iron chelator and thiourea, a scavenger of 
hydroxyl radical, were added to the culture, the cell death was not prevented in 
all cases (Kohanski et al., 2007). Usually the cell death is attenuated or delayed, 
which shows that the activation of the oxidative damage pathway can be more 
complex than described today. It could also mean that the hydroxyl radical 
driven cell death is not the only death pathway and could be responsible only 
for the initial fast killing in the wild type cells. A good example is the 
fluoroquinolone norfloxacin, which induces both the protein synthesis-
dependent and independent death pathways (Malik et al., 2007) while hydroxyl 
radicals probably contribute only to the protein synthesis-dependent pathway 
(Wang et al., 2010b). 
In addition, there are few other aspects that have to be considered in the 
described common death pathway. For example, it is admitted that some of the 
mutant strains have slower growth rate (Kohanski et al., 2007) that might be the 
reason of the slower killing rate as it is expected that faster growing cells are 
killed more rapidly. Also, the fact that most of the antibiotics kill bacteria in 
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anaerobic conditions (Hecht, 2005), where the formation of reactive oxygen 
species (ROS) is certainly diminished, rules out exclusiveness on the ROS 
mediated pathway. The drug concentrations used in the studies on the ROS 
mediated killing pathway were relatively low, which suggests that the eminence 
of the ROS depending killing seen by Collins and coworkers (series of studies 
reviewed by Kohanski et al., 2010) to be relevant only at low drug concent-
rations and is overshadowed by other killing pathways at higher antibiotic 
concentrations. 
 
1.4.5. Eagle effect 
An interesting aspect of antibiotic killing is so called Eagle or paradoxical effect 
(Eagle and Musselman, 1948). H. Eagle was first who noted that increasing 
concentration of the drug over the MBC value can have paradoxical effect in the 
way that the number of cells killed by the treatment decreased. In case of 
penicillin, this effect was shown to appear among different species and strains. 
Later the same effect has been observed also for different penicillins, 
cephalosporins and also aminoglycosides (Shah, 1982). Although Eagle effect 
has been observed frequently, the clinical significance of this phenomenon 
appears to be unclear (Shah, 1982, Amsterdam, 2005). 
There are several mechanistic hypotheses to explain the phenomenon of 
Eagle effect. For example, it has been suggested that at high concentration the 
inhibitors of cell wall synthesis can somehow slow down translation and 
prevent the cell growth, which is necessary for drug activity (Amsterdam, 
2005). Another proposed hypothesis states that overall inhibition of PBP-s at 
high concentration is less favoring to lysis as compared to the situation at lower 
concentrations or autolysins, which cleave and remodel peptidoglycan in 
normal conditions, are less activated at high concentrations of cell wall 
inhibitors (Rice and Bonomo, 2005). 
 
1.4.6. Toxin-antitoxin mediated killing 
A toxin-antitoxin system is a set of two or more closely linked genes where one 
codes for a toxic protein and another for an antitoxin. The toxin-antitoxin 
systems are divided into three subgroups by the nature of the antitoxin. In the 
type I systems, the antitoxins are small antisense RNAs that repress an 
expression of the toxins, whereas in the type II system antitoxins are proteins 
that neutralize toxins through the binding. The type III systems contain a small 
RNA antitoxin that also inactivates toxins through the formation of complex 
(Yamaguchi et al., 2011). 
The toxin-antitoxin systems were initially identified as addiction modules in 
plasmids (Gerdes et al., 1986) where they ensured inheritance of the plasmid by 
daughter cells. In the absence of plasmid the antitoxin, which is always more 
labile than the toxin, will be degraded faster, leading to the activation of the 
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toxin. Later the toxin-antitoxin modules were also found in the bacterial 
chromosomes where their functions are not completely understood (Yamaguchi 
et al., 2011).  
In the context of the current thesis the type II toxin-antitoxin systems are 
most relevant. These toxins are usually endoribonucleases that cleave mRNAs 
and thereby stop translation and bacterial growth. In addition, type II toxin-
antitoxin systems MazEF and ChpBK have been reported to induce bacterial 
killing or programmed cell death (PCD) (Kolodkin-Gal et al., 2009, Aizenman 
et al., 1996). It has to be noted that the story is contradictory as other 
laboratories have had difficulties to reproduce the results concerning the role of 
MazEF in PCD (Gerdes et al., 2005). One of the oppositional observation was 
that MazEF is causing rather reversible stasis and is not causing cell death 
(Pedersen et al., 2002). In return, the existence of “point of no return” was 
demonstrated (Amitai et al., 2004), meaning that inhibition by toxin is 
reversible only in certain timeframe and becomes irreversible later and will lead 
to the cell death.  
Afterwards, it was shown that MazEF mediated PCD has specific 
requirements. First, it is density- (Kolodkin-Gal et al., 2007) and growth-phase 
(Hazan et al., 2004) dependent and second, it is activated by a pentapeptide 
called extracellular death factor (EDF) (Kolodkin-Gal et al., 2007) in a strain-
specific manner (Kolodkin-Gal and Engelberg-Kulka, 2008). For example, the 
widely used K-12 wild type strain MG1655 is not capable to produce the EDF 
in substantial amounts and is therefore PCD deficient. 
In addition to various stressful conditions (UV, high temperature, oxidative 
stress) (Hazan et al., 2004), some classical bacteriostatic antibiotics like 
spectinomycin, chloramphenicol and rifampicin have also been demonstrated to 
activate PCD (Sat et al., 2001).  
The main players in the activation of PCD are MazF toxin and EDF. The 
different stressful conditions that are shown to activate PCD (Hazan et al., 
2004), are probably causing inhibition of translation or transcription, which will 
prevent expression of the antitoxin MazE resulting in to the activation of toxin 
MazF endoribonuclease activity. This, in turn, activates EDF production that, 
through the positive feedback loop, is leading to the further activation of MazF 
(Kolodkin-Gal and Engelberg-Kulka, 2008). It is proposed that the activation 
might come from direct interaction between those two molecules (Belitsky et 
al., 2011). 
The activation of MazF endoribonuclease activity leads to a massive 
cleavage of mRNA and to a decrease in the activity of translation (Zhang et al., 
2003). Nevertheless, translation is not completely shut down, and there is a set 
of proteins synthesized (Amitai et al., 2009). Some of those proteins have been 
identified as “death” or “survival” proteins according to the phenotype of the 
corresponding knock-out strain. If the deletion increases the survival, the 
protein is recognized as “death” protein and vice versa. It is hypothesized that 
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synthesis of “death” or “survival” proteins is heterogeneous between different 
cells in the way that some cells are induced to die and others to survive. 
In the case of PCD, two death pathways have identified: ROS-dependent and 
ROS-independent (Kolodkin-Gal et al., 2008). ROS dependent pathway is 
observed during the treatment with translation and transcription inhibitors. 
These drugs act probably by bulk inhibition of protein synthesis including ROS 
defense proteins. ROS-independent pathway is activated by DNA damaging 
drugs and could work via selective activation of death proteins. 
 
 
1.5. Bacterial responses to survive  
antibiotic treatment 
Bacteria can survive antibiotic treatment in different ways. Subsequently, I 
describe three ways: resistance, persistence and antibiotic tolerance. Special 
emphasis goes to the persistence as the Results part of this thesis is mostly 
focused on persistence. 
 
1.5.1. Resistance 
Resistance is bacterial ability to survive and grow in the presence of antibiotics. 
Resistance can be accomplished in several ways and usually it involves a 
special resistance gene that is providing a mechanism to overcome the toxic 
effect of antibiotic(s). 
Spread of resistance is a serious problem for healthcare system, and it has 
been tried to overcome the problem by introducing new antibiotics or even new 
classes of antibiotics, but for every new antibiotic clinically significant 
resistance has eventually emerged. For most of the drugs, the development of 
resistance has taken a year or two after the clinical introduction (Walsh, 2003, 
Levy & Marshall, 2004). There are also some exceptions. One example is 
vancomycin that was initially introduced in the 50s, but clinically significant 
resistance was reported almost 30 years later. The reason is that the use of 
vancomycin was very limited due to its toxicity and the development of new 
penicillins with better properties, resulting in vancomycin being used as a drug 
of last resort (Levin and Rozen, 2006). 
When talking about resistance, intrinsic and acquired resistance should be 
distinguished (Walsh, 2003). Intrinsic resistance is an innate ability of a 
bacterial species or strain to resist a particular antibiotic. It can be driven by any 
of the different resistance mechanisms described below. In addition, the 
intrinsic resistance can be caused by some trivial reasons e.g. anaerobic bacteria 
are resistant to aminoglycosides because of the lack of oxidative metabolism to 
drive uptake (Bryan and Kwan, 1983), Gram-negative bacteria are resistant to 
various drugs (for example, vancomycin and streptogramins) because of their 
inability to penetrate outer membrane (Walsh, 2003, Leclercq & Courvalin, 
7 
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1991), some bacteria have PBPs with low affinity to certain β-lactam drugs 
(Murray, 1990, Fontana et al., 1992, Bodey, 1990). Example of intrinsic 
resistance is also producers of antibiotics that must have mechanisms to protect 
themselves from the action of the drugs they are producing (Walsh, 2003). The 
resistance genes of antibiotic producers have been thought to be a potential 
reservoir for acquired resistance (Walsh, 2003).  
Multiple resistance mechanisms can reside in one single bacterium resulting 
in multidrug resistant bug often called “superbug”. Cases when multiple 
resistance markers are transferring together as a single unit are not rare, making 
acquisition of multi-resistance very simple (Nikaido, 2009). 
Resistance is achieved mainly by three groups of mechanisms – detoxifying 
antibiotics, altering target site and by reducing drug concentration. For every 
drug class most of the mechanisms have been identified, although their clinical 
relevance is variable. 
Antibiotic detoxification 
The mechanisms for antibiotic detoxification can be divided into two larger 
groups: degradation and modification of the drug. Probably the best known 
example of drug degradation involves β-lactamases which are opening the 
lactam ring of the β-lactam drugs thereby making the compounds unable to bind 
to transpeptidases (Livermore, 1995). In addition to β-lactams, degradation of 
the drug can also be clinically important resistance mechanism for strepto-
gramins (Mukhtar and Wright, 2005). 
Modification of the drug, on the other hand, involves the addition of 
different chemical substituents. Resistance by drug modification has been 
shown to be clinically important for aminoglycosides (Walsh, 2003), strepto-
gramins (Mukhtar and Wright, 2005), lincosamides (Leclercq, 2002), phenicols 
(Murray and Shaw, 1997) and quinolones (Robicsek et al., 2006). 
Altering the drug binding site 
Altering the drug target is relatively widespread mechanism of resistance and is 
clinically significant to most of the drug classes. This mechanism could work 
through mutation(s) in the gene coding the target, modification of the target via 
a posttranscriptional mechanism or acquiring additional, insensitive copy of the 
target (Walsh, 2003). An example of an easily acquired resistance by the change 
in the gene coding the target is a mutation of the gene coding for RNA 
polymerase leading to rifamycin resistance (Tupin et al., 2010, Floss & Yu, 
2005). This resistance is selected for so fast that rifamycins are usually co-
administered with other drugs (Wallis et al., 2008). 
Resistance against ribosome targeting drugs can often be established by 
mutations in rRNA genes (Rice and Bonomo, 2005). However, this mechanism 
is not clinically significant as rRNAs are usually encoded in multiple operons 
and simultaneous selection for all rRNA genes, together with gene conversion 
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between different operons is not very likely (Prammananan et al., 1999, 
Klappenbach et al., 2001). Still, some pathogens like Rickettsia prowazekii 
(Andersson et al., 1995) and Mycoplasma pneumoniae (Bercovier et al., 1986) 
harbor single rRNA operon, and for the latter a clinically significant resistance 
through mutations in the 23S rRNA gene has been reported (Morozumi et al., 
2010). On the other hand, the mutations in ribosomal proteins can be and are 
clinically significant as ribosomal proteins are encoded by a single gene 
(Wilcox et al., 2001). 
Clinically significant resistance through changes in rRNA is usually 
achieved by the active mechanism of modifying nucleotides (Douthwaite et al., 
2005). For example, resistance against macrolides (erythromycin and other 
older generation macrolides) is achieved by methylation of 23S rRNA at 
nucleotide A2058. This modification decreases the affinity also against linco-
samides and B type streptogramins. This type of resistance is described as 
macrolide-lincosamide-streptogramin B (MLSB) resistance phenotype. The 
methylation can be constitutive or induced in the presence of the drug (Roberts 
et al., 1999). 
Famous “superbug” MRSA (methicillin-resistant Staphylococcus aureus) is 
another example of acquired resistance (Walsh, 2003). Methicillin was 
introduced in 1950s to overcome penicillin resistance among Gram-positive 
pathogens that was achieved by hydrolysis of the drug by β-lactamases. Later, 
when MRSA started to spread all over the world, it was noted that in 90% of 
clinical isolates the resistance was not acquired through more effective  
β-lactamase but by additional copy of PBP2 with low β-lactam binding affinity. 
Reducing drug accumulation 
Low levels of antibiotics inside the cell can be achieved by actively exporting 
the drug molecules out from the cell or reducing permeability of the cell 
envelope. 
Active efflux can be clinically relevant for many different classes of anti-
biotics (for example, β-lactams, macrolides, A type of streptogramins, fluoro-
quinolones and tetracycline). Efflux pumps can be run on the proton motive 
force or on the energy from ATP hydrolysis, although the latter is less common 
(Walsh, 2003). In addition, there are also reports about Na+ driven efflux pumps 
(Morita et al., 2000, Huda et al., 2001).  
Every bacterium has a relatively wide variety of efflux pumps to transport 
out wastes and other unwanted molecules. Many of these pumps do not have 
strict substrate specificity (Walsh, 2003, Piddock, 2006). The result is that many 
of these pumps have the ability to pump out some antibiotics. For example, P. 
aeruginosa intrinsical resistance to various antibiotics originates partially from 
efflux pumps (Zavascki et al., 2010). 
Often the pumps can carry out a wide variety of drugs (named accordingly – 
multidrug efflux pumps) and confer multidrug resistance phenotype. 
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Conversely, some pumps, for example, tetracycline efflux pumps, tend to have 
rather narrow specificity (Walsh, 2003, Chopra & Roberts, 2001). 
Reduction of permeability of the cell envelope can result from changes in 
composition of the outer membrane. Many hydrophobic drugs (macrolides, 
aminoglycosides, rifamycins etc.) are entering the cell by diffusion via outer 
membrane by hydrophobic interactions. Therefore, changed composition of the 
membrane can lead to the resistance to those drugs (Delcour, 2009).  
Hydrophilic drugs (like β-lactams, also tetracyclins and fluoroquinolones), 
on the other hand, are exploiting porins that are functioning for transporting 
small molecular compounds to the cell. Resistance against those drugs can be 
achieved by changing porin profile in the outer membrane. This could include 
loss or sever reduction of the amount of porins. In addition, porin specificity 
could be changed by mutations (Nikaido, 2003, Delcour, 2009). 
Other mechanisms 
Resistance can be achieved also by other mechanisms. For example, tetra-
cycline resistance can be mediated by so called ribosomal protection proteins. 
They are structurally similar to elongation factors and can bind to the ribosomal 
A-site where they can with the help of energy from GTP hydrolysis figuratively 
wipe tetracyclines off from ribosomes (Connell et al., 2003).  
 
1.5.2. Persistence 
Joseph Bigger reported already at the early dawn of the antibiotic era (Bigger, 
1944) that penicillin does not sterilize bacterial culture. Today’s researchers 
from resistance era would have probably thought that those non-dying cells are 
some sort of indication of resistance. Bigger, on the other hand, understood that 
the phenomenon he has encountered, is something completely different. In fact, 
he suggested that those penicillin insensitive cells are quiescent or dormant and 
therefore survive the treatment, as it was already known that penicillin can kill 
only actively growing cells (Hobby et al., 1942). 
Persisters are defined as bacterial cells that survive the treatment by 
bactericidal antibiotics and are capable of continuing growth after removal of 
the drug. This phenomenon is distinguished from resistance by the fact that after 
reinoculation a new heterogeneous culture will be formed, where most of the 
cells are again sensitive to the drug, making it a phenotypic not a genotypic trait 
(Lewis, 2010, Bigger, 1944). It has been assumed that persisters are a 
physiologically discrete subpopulation differing from the bulk of the cells that 
are killed slowly because they are dormant. Bacterial time-kill curves are 
usually having the shape of biphasic exponential decay formed from fast and 
slow phases (Fig. 2). Some authors have clearly pointed out that persisters are 
only the cells forming the slow phase (Dhar & McKinney, 2007, Balaban et al., 
2004). Therefore, there is a risk that when antibiotic treatment is too short the 
read of colony forming units (CFU) does not represent persister frequencies 
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correctly as it might also contain a significant number of normal, fast killed 
cells (at this moment not yet killed). Regular antibiotic treatment lengths in 
published papers are usually equal or longer than 3 hours, which is enough to 
show the true persister frequency in growing culture incubated in a rich medium 
(like LB) (Keren et al., 2004a, Jõers et al., 2010). However, there is a risk for 
inappropriate (physiologically irrelevant) persister estimation arising from the 
common but primitive definition of persistence. To avoid this risk it should be 
clearly emphasized that antibiotic treatment should be long enough, and a 
physiologically relevant definition for persisters should be brought up. 
 
 
Figure 2. Biphasic killing of bacteria. Total population of bacteria (1) is killed by 
biphasic manner. Fast phase (2) is composed of normal cells and slow phase (3) is 
formed by persisters. Tolerant cells (4) are killed slowly. 
 
 
Although persisters have been known for a long time, the nature behind this 
phenomenon is not clear. One reason for this is their very low frequency that is 
typically reported being in the range of 10–4–10–6 (Moyed & Bertrand, 1983, 
Keren et al., 2004a). Their scarcity makes them very difficult to study, so that 
the first, more profound, series of studies were published about 40 years after 
the first initial report in this field by Moyed and colleagues (Scherrer & Moyed, 
1988, Moyed & Broderick, 1986, Moyed & Bertrand, 1983, Black et al., 1991, 
Black et al., 1994). After Moyed, persisters came to the spotlight again in the 
beginning of the 21st century (Spoering & Lewis, 2001, Sinhg, 2002) and are 
relatively actively studied up to date. 
Persisters have been reported to be found in numerous bacterial species (De 
Groote et al., 2009). In addition to bacteria, persister-like behavior has been 
reported also among fungi (LaFleur et al., 2006, Jabra-Rizk et al., 2004) and 
cancer cells (Sharma et al., 2010).  
 
 
8 
30 
 
Mechanism of persister formation 
Mechanistic studies on persisters have been conducted mainly on E. coli, and 
most of the results described below in this paragraph accounts for the E. coli, 
and therefore the organism is mostly not mentioned. Also, some data originating 
from other type of organisms have been published and are mentioned here 
separately. 
First locus to be connected with persistence was hipBA (Moyed and 
Bertrand, 1983) that codes antitoxin-toxin module where the toxin is an EF-Tu 
targeting kinase (Maisonneuve et al., 2011). hipBA locus was identified when 
mutants with increased persistence were selected. One of the strain identified 
was hipA7 (high persistent) with the persister level increased about three orders 
of magnitude (Moyed and Bertrand, 1983). Later, the hipA7 strain was found to 
carry two point mutations in hipA gene (Korch et al., 2003). These mutations 
are expected to result in weaker binding between the toxin and antitoxin 
(Maisonneuve et al., 2011). It is thought that the higher average free toxin level 
would lead to a situation where the number of cells, exceeding the threshold 
level of toxin causing dormancy, is increased and therefore more persisters are 
formed. This is supported by a study where ectopic over-expression of HipA 
toxin caused dormancy of single cell when the toxin concentration was over a 
certain threshold and the length of dormancy was depending on how long the 
toxin concentration over the threshold (Rotem et al., 2010). 
Two types of persisters have been characterized – type I and II. Classical 
persister assay is performed with growing culture where the inoculum is 
originating from overnight (stationary phase) culture. With this setup it has been 
shown through continuous dilution and growth cycles that persisters are 
eventually diluted out, meaning that they are originating from the initial 
stationary phase inoculum (Keren et al., 2004a). This kind of persisters are the 
cells that have not yet started to grow actively and are called type I persisters 
(Balaban et al., 2004). 
Type II persisters are forming during the growth, when actively growing 
cells are switching to slowly growing or non-growing state. In the wild type E. 
coli the level of type II persisters is even lower than the level of type I 
persisters. Therefore, the type II persisters are usually masked by type I 
persisters, making them hard to study. There is another high persistent mutant 
hipQ (Wolfson et al., 1990) that has an increased level of type II persisters 
(Balaban et al., 2004). HipQ has not gained much attention, the strain is not 
well characterized and the mechanism behind it is not known. 
Persisters are identified also in biofilms (Spoering and Lewis, 2001) and 
sometimes their level is measured in stationary phase culture (Ma et al., 2010, 
Li & Zhang, 2007, Keren et al., 2004a). As those habitats reflect non-growing 
or slowly growing environments, care should be taken when drawing 
mechanistic parallels with persisters from growing cultures.  
Persisters are dormant during the antibiotic treatment and are starting to 
grow later, after the antibiotic is removed. Bulk of the persisters are thought to 
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originate from stationary phase inocula, that is supported by data showing that 
the persister levels reflect the kinetics of awakening from dormancy (Jõers et 
al., 2010). Surprisingly, it was noticed (Gefen et al., 2008) that in a narrow time 
window, right after dilution, supposedly dormant cells were also able to 
synthesize proteins. This suggests that complete differentiation into persister 
state might not happen in stationary phase, rather after inoculation into the fresh 
medium. Gefen and colleagues saw also that the exposure to bactericidal 
antibiotics during this narrow time window significantly reduced the persister 
level, but this result was conflicted by a later paper (Jõers et al., 2010), although 
the results are not directly comparable as different growth conditions and strains 
were used. 
Although during the last 10 years several serious attempts have been made, 
the molecular mechanisms responsible for persister formation are largely 
unknown. Three reports analyzing the gene expression of E. coli persister cells 
(Shah et al., 2006, Keren et al., 2004b) and one in Mycobacterium tuberculosis 
(Keren et al., 2011) are available. It turned out that the persister transcription 
profile differs from stationary and exponential phase cells (Shah et al., 2006). 
Large sets of genes were down regulated in persister cells including several 
metabolism and flagellum related genes, a response that is expected in dormant 
cells (Shah et al., 2006, Keren et al., 2011). A smaller set of various genes, with 
variable functions, were up regulated. These included different stress response 
related genes, which is consistent with the persister survival function but does 
not explain dormancy (Shah et al., 2006, Keren et al., 2011). Another 
outstanding set of up-regulated genes are coding for toxin-antitoxins (TAs) 
(Shah et al., 2006, Keren et al., 2004b, Keren et al., 2011). Many of the E. coli 
toxins are endoribonucleases (Maisonneuve et al., 2011) and HipA is protein 
kinase targeting EF-Tu (Schumacher et al., 2009). As toxins are able to stop 
macromolecular synthesis, their activity could be a direct cause for stasis and 
dormancy. Surprisingly, only few single gene knock-out mutants of the TA 
systems showed lower persister frequency, and even this effect is observed in 
specific conditions or background (Shah et al., 2006, Kim & Wood, 2010, 
Keren et al., 2004b, Harrison et al., 2009). The small effect of deleting TA 
systems was explained by a possible redundancy between different TA systems 
and the need for multiple knock-outs, for more significant effects, was 
suggested. Recently, a report of 10 TA system knock-out was published and 
indeed, a 200 fold drop in persister frequency was demonstrated. The reduction 
was progressive, depending on the number on TA systems deleted 
(Maisonneuve et al., 2011). Also, in M. tuberculosis the deletion of some toxins 
has been found to decrease persister level in vitro, but the in vivo significance of 
this effect is in question, as no effect was seen in a mouse model (Singh et al., 
2010). 
Different screens have been run to identify genes that could change persister 
frequency: E. coli (Ma et al., 2010, Hurwitz et al., 1981, Hansen et al., 2008) 
and P. aeruginosa (De Groote et al., 2009) knock-out library screens, and E. 
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coli transposon (Li and Zhang, 2007) and over-expression (Spoering et al., 
2006) library screens. Indeed, numerous genes, coding various unrelated 
proteins, were found to influence persister level, but no clear mechanism has 
been elucidated from these data so far. 
It has thought that the mechanism leading to persistence in the presence of 
various drug classes is the same. Contrary to that, it was recently reported that 
there is no correlation between persister levels upon treatment with ampicillin, 
norfloxacin or streptomycin (representatives of different drug classes) as 
measured in cultures of natural E. coli isolates (Stewart and Rozen, 2011). The 
problem with this report is that the drug concentrations used were much lower 
than usual in persister assays – the concentrations were only slightly higher than 
the MIC. As MIC and MBC values of different strains do not have to be rigidly 
connected to each other, the killing efficiencies of different drugs might have 
been varying resulting in diverse levels of drug-specific persisters. 
In addition, it has been noted that the induction of SOS response is crucial 
for persister formation only when bacteria are treated with fluoroquinolones 
(Dorr et al., 2009). It is proposed, that, in addition to the protective effect of 
SOS response, the synthesis of the membrane protein TisB is induced by SOS 
response, which could cause the loss of proton motive force and the formation 
of dormant cells (Dorr et al., 2010).  
Various conditions have been identified to induce the formation of 
persisters. For example, over expression of toxins and other unrelated proteins, 
shown to be toxic, have been reported to increase persistence (Vazquez-Laslop 
et al., 2006, Shah et al., 2006, Korch & Hill, 2006, Kim & Wood, 2010, Keren 
et al., 2004b, Harrison et al., 2005, Dorr et al., 2010). Also, the addition of 
quorum sensing molecules could increase persistence (Moker et al., 2010), 
although the addition of spent medium to early exponential phase cells does not 
induce pesisters in E. coli and P. aeruginosa (K. Lewis, unpublished data). For 
mycobacteria, it has been shown that persister phenotype can be induced also in 
macrophages of zebrafish larvae. In this case, the bacterial cells have lost 
sensitivity to antibiotics through activation of efflux pumps and this 
phenomenon is associated with replicating bacterial populations (Adams et al., 
2011). For biofilm cells, it has been reported that antibiotic insensitivity is not 
caused just by the passive effects of growth arrest; it is rather mediated by 
active starvation responses, reducing the oxidant stress (Nguyen et al., 2011). 
Ecological significance of persistence 
Persisters have been suggested to be an adaption for survival in fluctuating 
environments (Kussell & Leibler, 2005, Kussell et al., 2005). Diversity of 
phenotypes, used as “insurance policy” in changing environmental conditions, 
is established in ecology and population genetics as a bet-hedging strategy 
(Beaumont et al., 2009). Persister state could be achieved via stochastic 
switching or by switching in response to sensing the changes in the 
environment. Responsive switching could be energetically more costly as it 
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would need the apparatus for sensing and reacting, and therefore, would be 
more favored if the environment is changing more frequently. Stochastic 
switching would be more favored when changes in the environment are not so 
frequent. In this case the switching rate would need to be adjusted to the 
frequency of environmental changes. In addition, catastrophic changes in the 
environment would favor stochastic switching as in this case there would be no 
time to respond (Kussell and Leibler, 2005). 
It has been also proposed that persisters could simply be the outcome of 
senescence (Klapper et al., 2007). Bacterial cell can accumulate damages, for 
example, oxidative damage (Fredriksson and Nystrom, 2006). It has been 
demonstrated that a subpopulation of stationary phase cells with lower ability to 
form colonies has a higher level of carbonylated (oxidatively damaged) proteins 
(Desnues et al., 2003). This leads to the hypothesis that the persistence 
phenotype could, at least partially, reflect random nature of cell damage, as the 
cells that acquired more damage during stationary phase are resuming growth at 
a slower rate as compared to cells with lower level of damage. Several 
molecular mechanisms could be involved in senescence. For example, each 
bacterial cell has an old pole and a new pole that originates from last division. It 
has been shown that cells inheriting old pole during division, have decreased 
growth rate. Moreover, the decrease of growth rate of the cell, inheriting the old 
pole, is accumulating during the consecutive divisions (Stewart et al., 2005). 
The cause of this effect could be asymmetric accumulation of damaged cell 
components (Lindner et al., 2008). This effect could explain the formation of 
type II persisters during growth. It has to be noted that also contradictory 
observations have been made, where the ageing pole did not have any effect on 
the growth rate whatsoever (Wang et al., 2010a). 
Persisters and infectious diseases 
Infectious diseases are often hard to treat even when the pathogen is not 
resistant. Good examples are persistent or chronic infections that need 
prolonged treatment (for example, syphilis or tuberculosis) or reappear after 
recovering. Chronic infections are often accompanied by biofilms. Persisters 
residing in biofilms are thought to be the source of recurrence (Lewis, 2010). A 
proposed model suggests that antibiotics are killing most of the bacteria and the 
immune system eliminates bacteria escaping antibiotic treatment. Persister cells 
residing in biofilm will be protected from the immune system and after the drop 
in antibiotic concentration they could repopulate the biofilm again and cause 
reappearance of the infection. 
Potential causality between persisters and therapy failure is supported by 
selection of hip mutants in vivo. This is the case for cystic fibrosis patients with 
P. aeruginosa infections (Mulcahy et al., 2010). This infection is incurable, but 
periodic dosing of antibiotics, lasting years, can relieve symptoms. Eventually 
long lasting and periodic treatment is leading to the rise of strains with about 
100 times higher persister level with unchanged MIC. Similar phenomenon has 
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been observed for long term oral carriage of eukaryotic Candida albicans 
suggesting wider impact of persister phenomenon and hip strains (Lafleur et al., 
2010). As the testing of persister frequencies is not common in clinical labs, it is 
explaining why persisters and high persister mutants are overlooked among 
chronic infections. 
Currently persisters have been recognized as an issue in clinical micro-
biology and efforts are being made to develop approaches to fight persisters. 
For example, a chemical library has been screened and a compound reverting 
persister cells to antibiotic-sensitive cells, and therefore mediating their death, 
has been identified (Kim et al., 2011). Similar effect has also been observed 
with certain metabolites (Allison et al., 2011). 
 
1.5.3. Antibiotic tolerance 
Third way how bacteria circumvent lethal activity of antibiotics is antibiotic 
tolerance. This term was initially introduced by clinical microbiologists to 
describe a new type of bacterial response to antimicrobials (Tomasz et al., 
1970). In 1970 new types of mutant pneumococcal strains were characterized. 
Those strains had unchanged MIC, but the rate of antibiotic induced killing was 
decreased, or even reduced to the level that they didn’t lose viability at all.  
Unaffected MIC makes antibiotic tolerance different from resistance. Anti-
biotic tolerance differs also from the persistence phenomenon, as it comprises 
all cells in the genetically homogeneous population, while persistence affects 
only small subpopulation of the cells. In addition, tolerance is heritable 
(genotypic) trait, as opposed to persistence that is an example of phenotypic 
trait (Keren et al., 2004b). 
Nonetheless, during the last decade the term antibiotic tolerance and a linked 
term phenotypic tolerance have often been used in the meaning of persistence 
(Wiuff et al., 2005, Spoering et al., 2006, Lewis, 2001, Hansen et al., 2008, 
Dhar & McKinney, 2007). One possible reason lays in the fact that the last in-
depth disquisitions on antibiotic tolerance remain behind decades (Tuomanen et 
al., 1986, Handwerger & Tomasz, 1985), although there are several more recent 
studies covering the topic in its original meaning (Moscoso et al., 2010, 
Mitchell & Tuomanen, 2002, Bizzini et al., 2010, Andres et al., 2005) and it is 
also clearly stated in several handbooks (Smith, 2004, Amsterdam, 2005). There 
are also a few recent reports that are emphasizing the differences between those 
two phenomena (Levin & Rozen, 2006, Gefen & Balaban, 2009). 
The best way to clarify the difference between persistence and antibiotic 
tolerance, in its original meaning, is on example of antibiotic kill curve. Usually 
antibiotic kill curves can be simplified as biphasic exponential decay (although 
actually it could also be multiphasic) (Fig. 2). First, the fast phase reflects 
killing of the major population of the cells and this killing rate is changed in 
case of changes in antibiotic tolerance. The second, and slower killing phase 
reflects persisters and usually their absolute level is affected, instead of killing 
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rate. The killing rate can also be changed, but for persistence this is not 
commonly evaluated. 
Even among the clinical microbiologist the term antibiotic tolerance has 
problems with multiplicity of definitions (Tuomanen et al., 1986, Handwerger 
& Tomasz, 1985). For clinical purposes the assessment of antibiotic tolerance 
includes comparing the ratios of MBC to MIC. Generally ≥ 32 fold ratio has 
been taken as a marker for tolerant strain (Sabath et al., 1977, Meylan et al., 
1986, Goessens et al., 1984), although higher and lower ratios are also used 
(Handwerger and Tomasz, 1985). It is important to keep in mind that MBC 
value is acquired through the endpoint measurement. This means that it does not 
give information about the rate of killing that was originally used to define 
antibiotic tolerance. It has to be emphasized that the most accurate way to 
measure antibiotic tolerance would be through the killing curve. 
Antibiotic tolerance is sometimes divided into two classes: phenotypic and 
genotypic tolerance (Tuomanen et al., 1986). Usually, genotypic tolerance 
reflects mutant strains that behave differently from reference or the wild type 
strain in regular growth conditions in the presence of antibiotics. The term 
genotypic tolerance can also be also used for comparing two or more unrelated 
bacterial strain. 
Phenotypic tolerance characterizes growth conditions where bacteria do not 
respond or respond slower to antibiotic. The phenomenon was described already 
in 1940s (Hobby et al., 1942), although it was named much later (Tuomanen et 
al., 1986, Handwerger & Tomasz, 1985). A good example of phenotypic 
tolerance is stationary phase culture that is not sensitive to most of the 
antibiotics.  
The antibiotic tolerance is usually observed in cases of antibiotics causing 
cell lysis, for example, β-lactams or glycoprotein antibiotics (e.g. vancomycin). 
Also, the mechanistic studies on the tolerance are mainly done with those 
antibiotics (Tuomanen et al., 1986, Mitchell & Tuomanen, 2002). Lysis caused 
by those antibiotics is conducted via autolysins that are constitutively expressed 
extracellular enzymes. In normal conditions their activity is controlled but they 
can be activated in certain conditions (for example, during treatment with the 
antibiotics mentioned earlier) (Mitchell and Tuomanen, 2002). Antibiotic 
tolerance is caused by the absence of autolytic activity and it can be achieved by 
the loss of autolysin expression or the inability to activate autolysins. There are 
several genes whose deletion diminishes autolysin expression, but their role in 
the regulation of expression of autolysins is not completely clear (Novak et al., 
2000a, Novak et al., 1998, Charpentier et al., 2000). At the same time, the 
clinical isolates of the tolerant strains are expressing autolysins, meaning that 
clinically important way for formation of tolerance is through the changes in the 
activation of autolysins. Some loci, coding for proteins involved in the 
activation pathway of autolysins (including a two-component regulator system), 
have been described (Rice et al., 2003, Novak et al., 1999, Novak et al., 2000b, 
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Groicher et al., 2000), but our understanding of the pathway is far from 
complete (Rice & Bayles, 2008, Mitchell & Tuomanen, 2002). 
 
 
1.6. Trans-translation and antibiotic susceptibility 
Various genetic determinants can influence intrinsic antibiotic susceptibility of 
bacteria (Keiler et al., 1996), including many whose dominant function is not 
resistance. One such example is transfer-messengerRNA (tmRNA) that has 
been reported to decrease susceptibility to various inhibitors of protein synthesis 
(Vioque & de la Cruz, 2003, de la Cruz & Vioque, 2001, Abo et al., 2002). 
tmRNA, also known as 10Sa RNA, is coded by the gene ssrA. It is a 
molecule that is directing the process called trans-translation and is highly 
conserved among eubacteria (Gueneau de Novoa and Williams, 2004). tmRNA 
is an interesting bifunctional RNA molecule combining the characteristics of 
tRNA and mRNA. Its tRNA like domain resembles tRNAAla and can be 
aminoacylated with alanine from the 3’ end. tmRNA also contains a reading 
frame, which is coding a tag added to the C terminus of nascent peptides. 
Trans-translation recycles ribosomes stalled on mRNA (Keiler et al., 1996). 
There can be several reasons for stalling, for example, mRNA might lack stop 
codon at the 3’ end because of truncation (Keiler et al., 1996) or improper 
transcription (Ivanova et al., 2004). Stalling can be caused also by rare codons 
(Roche and Sauer, 1999) or insufficient termination (Hayes et al., 2002, Collier 
et al., 2002). In all mentioned cases, ribosomal A-site is empty which is 
necessary for the tmRNA to bind and function. 
Trans-translation starts with the binding of the tRNA-like region of the 
tmRNA to the A-site of the ribosome. After the transpeptidation reaction, the 
problematic mRNA will be replaced with the mRNA-like region of the tmRNA, 
which codes short signal for proteolysis. Translation will continue and will 
result in the tagging of the synthesized protein (Keiler, 2008). 
Initially it was suggested that the function of trans-translation is to recycle 
ribosomes, stalled on mRNA, to ensure translational capacity (Keiler et al., 
1996). The process would also include the removal of potentially toxic 
truncated proteins and problematic mRNAs causing stalling. In light of recent 
evidence, it has been suggested that the function of trans-translation is not to 
maintain translational capacity of the cell but rather the release of some 
particular problematic ribosomes (Hayes and Keiler, 2010). For example, 
ribosomes that stall during co-translational protein secretion may cause 
problems, as the translocon complex will be degraded. Release of the stalled 
ribosome by tmRNA could help to prevent the degradation. In addition, it has 
been hypothesized that misfolded nascent peptides may cause translational 
stalling to give them extra time to fold properly. In case the folding fails, the 
potentially toxic misfolded proteins would be released from the ribosome by 
trans-translation system and degraded (Hayes and Keiler, 2010). 
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In addition to releasing stalled ribosomes, tmRNA has broader role on the 
cell physiology. For example, tmRNA regulates the expression of some genes 
(Garza-Sanchez et al., 2011, Abo et al., 2000). In addition, it is known that 
deletion of ssrA can change cell physiology – virulence, sporulation, cell cycle 
progression and stress responses can be affected (reviewed in Keiler, 2007). At 
the same time, the deletion of ssrA can also be lethal for some organisms 
(Huang et al., 2000, Hayes & Keiler, 2010). The lethality is associated with 
presumably non-active variant of ArfA, a protein which was recently 
demonstrated to rescue E. coli stalled ribosomes in tmRNA-independent way 
(Chadani et al., 2010). Similar properties have been also demonstrated for 
another protein called YaeJ (Chadani et al., 2011). 
10 
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2. RESULTS AND DISCUSSION 
2.1. Objectives of the present study 
There are various factors that can influence sensitivity of bacteria to antibiotics. 
For example, over-expression (Vazquez-Laslop et al., 2006, Li & Nikaido, 
2009) or deletion (Keren et al., 2004a) of several genes can change bacterial 
susceptibility to different antibiotics. Inhibitors of protein synthesis have been 
reported to be more potent against trans-translation deficient strains (Vioque & 
de la Cruz, 2003, de la Cruz & Vioque, 2001, Abo et al., 2002). In addition to 
genetic factors, the growth conditions can have an impact on the effectiveness 
of antibacterial drugs (Hobby et al., 1942). 
Effect of the previously mentioned factors on antibiotic susceptibility can be 
observed on the level of the whole population, for example, the killing rate of 
the whole population or growth at the presence of an antibiotic. At the same 
time, the effects can be subpopulation specific. One example of such sub-
populations is persisters. Several genes (Spoering et al., 2006, Ma et al., 2010, 
Li & Zhang, 2007, Hansen et al., 2008, De Groote et al., 2009), compounds 
(Allison et al., 2011) and growth conditions have been shown to change 
persister level or susceptibility to antibiotic (Keren et al., 2004a, Jõers et al., 
2010). 
As there are still many unknowns in the subjects previously mentioned, the 
general aim of this thesis was to identify and further characterize the factors 
which influence the sensitivity of E. coli to various antibiotics. For clarity, the 
work is divided into following aims: 
 To study further antibiotic susceptibility of tmRNA deficient E. coli. 
 To develop a flow cytometrical assay to study cell division at the single 
cell level. 
 To explore heterogeneity of the cell division at the single cell level 
through different growth stages. 
 
 
2.2. The lack of tmRNA increases the bactericidal  
activity of aminoglycosides and the susceptibility  
to inhibitors of cell wall synthesis (I) 
There are reports that tmRNA deletion results in higher sensitivity to inhibitors 
for protein synthesis compared to wild-type strains(Vioque & de la Cruz, 2003, 
de la Cruz & Vioque, 2001, Abo et al., 2002). Therefore, it has been suggested 
that tmRNA can recycle ribosomes that are stalled by antibiotics inhibiting 
protein synthesis. At the same time, as mentioned earlier, tmRNA can play a 
role in various aspects of bacterial physiology. This is raising the question, does 
the inactivation of the ssrA increase the sensitivity also to drugs which have 
other targets than ribosome? 
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In those few reports, describing the sensitizing effect of ssrA removal, only 
the growth inhibitions have been measured. We wanted to know, if the deletion 
of ssrA influences bactericidal activities of the drug. 
To test those possibilities, we compared antibacterial effects of 14 
antibiotics, 6 of them having a different target from ribosome, on the wild-type 
and ∆ssrA strains. Two approaches were used. First, the growth inhibition of the 
two strains was measured. Second approach, testing the possible variability on 
bactericidal activity, was carried out with drugs which showed differences 
between the wild-type and ∆ssrA strains. 
 
2.2.1. Growth inhibition 
Concentration ranges for 14 antibiotics were selected from low or no inhibition 
to maximum inhibition. The experiment was started with dilution of overnight 
or exponential phase cultures into fresh media containing an antibiotic and after 
12 hours of aerobic incubation the optical density was measured. As overnight 
and exponential phase cultures were giving similar drug sensitivity patterns, 
only the results of overnight cultures are shown (I, Fig. 1 and 2). 
In agreement to previous reports (Vioque & de la Cruz, 2003, de la Cruz & 
Vioque, 2001, Abo et al., 2002), the ∆ssrA was more sensitive to several inhi-
bitors of protein synthesis as compared to wild type (I, Fig. 1). Most prominent 
effects were seen with kanamycin, streptomycin and erythromycin. Smaller 
difference was observed in the case of chloramphenicol and puromycin. No 
significant difference was seen with tetracycline, clindamycin and spectino-
mycin. 
Is it possible to find parallels between mechanisms of action of ribosome 
targeting antibiotics and their sensitization effect of the ∆ssrA strain? 
Antibiotics that showed different activity between the test strains are inhibiting 
translation in various manner: erythromycin binds to the ribosome exiting 
tunnel and is sterically blocking the elongation of nascent peptide and is causing 
the drop-off of peptidyl-tRNA (Tenson et al., 2003, Lovmar et al., 2004); 
kanamycin and streptomycin are causing misreading of mRNA (Magnet and 
Blanchard, 2005); puromycin is a structural analog of tyrosyl-tRNA and is 
acting as acceptor in transpeptidation reaction thereby interfering with the 
binding of aminoacyl-tRNA to the A-site (Spahn and Prescott, 1996); 
chloramphenicol inhibits peptidyl transfer (Spahn and Prescott, 1996). 
Antibiotics that had equal effectiveness against the wild-type and ∆ssrA strain 
are inhibiting translocation (spectinomycin) (Magnet and Blanchard, 2005), 
hindering the binding of aminoacyl-tRNA to the A-site (tetracycline) (Chopra 
and Roberts, 2001) or blocking peptidyltransferase reaction and causing the 
drop-off of peptidyl-tRNA (clindamycin) (Tenson et al., 2003). 
It turns out that the ∆ssrA strain has different sensitivity to several anti-
biotics with partially overlapping mechanisms. Examples are chloramphenicol 
and tetracycline (interfers the binding of aminoacyl-tRNA to the A-site), 
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erythromycin and clindamycin (drop-off of peptidyl-tRNA), chloramphenicol 
and clindamycin (blocks peptidyl transferase reaction). This leads to the 
conclusion that the molecular mechanism of protein synthesis inhibitors is not 
enough to predict the sensitization effect of ssrA deletion. 
Interestingly, we saw a difference between the wild type and ∆ssrA strain 
also in the case of some antibiotics not targeting the ribosome (I, Fig. 2). The 
sensitization effect of ssrA deletion was observed for ampicillin and fosfo-
mycin, which are both inhibitors of the cell wall synthesis, although they are 
blocking different steps in the process (Walsh, 2003). Inhibitors of RNA 
polymerase (rifampicin), DNA topoisomerase (norfloxacin and ofloxacin) and 
dihydrofolate reductase (trimethoprim) (Walsh, 2003) did not cause significant 
growth differences between the strains. 
Link between the cell envelope and the ribosome targeting antibiotics could 
arise from the hypothesis that trans-translation system could be important for 
rescuing SecYEG translocon from the degradation, when translating ribosomes 
are stalled by antibiotics during co-translational translocation (Hayes and 
Keiler, 2010). It has been reported that drugs blocking translation elongation are 
inducing degradation of SecY and SecG that could lead to sever growth 
impairment or lethality (van Stelten et al., 2009). The sensitization effect of 
ssrA deletion for some antibiotics could be the consequence of different 
selective inhibition of protein synthesis as some drugs could inhibit more 
effectively proteins translocated to the inner membrane than others.  
Interestingly, antimicrobial effect of some protein synthesis inhibitors also 
operates through the cell envelope. For example, aminoglycosides are causing 
misreading of the mRNA during translation (Magnet and Blanchard, 2005) 
resulting in the formation of proteins that are potentially misfolded and are, 
through the exposed hydrophobic regions, prone to mislocalize into the 
membranes and interfere their functioning.  
Trans-translation and inhibitors of the cell wall synthesis could be linked 
also by the fact that tmRNA is tagging SecM protein, which is a regulator of 
SecA expression (Collier et al., 2004). SecA is an ATPase that is targeting 
proteins into the SecYEG translocon (Veenendaal et al., 2004). It is possible 
that the lack of trans-translation is causing perturbations in the export of 
proteins from the cytoplasm, and therefore the cells are not capable to respond 
adequately to extracellular stresses. 
Sensitization by defective trans-translational machinery could also be a 
result of the changed general physiology of the cell that tmRNA is known to 
cause, as mentioned earlier. At the same time, different antibiotics have been 
shown to induce various stress responses (VanBogelen & Neidhardt, 1990, 
Shapiro & Baneyx, 2002, Sabina et al., 2003, Goh et al., 2002, Bianchi & 
Baneyx, 1999). It has been reported that ribosome targeting antibiotics, 
kanamycin, streptomycin and puromycin, which caused a greater growth 
inhibition of ∆ssrA strain compared to the wild type strain (I, Fig. 1), are 
inducing the heat shock response (VanBogelen and Neidhardt, 1990). 
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Interestingly, E. coli ∆ssrA strain is also sensitive to heat shock (Komine et al., 
1996, Karzai et al., 1999). On the other hand, ssrA deletion caused sensitization 
to erythromycin and chloramphenicol (I, Fig. 1) which are inducing cold shock 
response but not to tetracycline that induced the same response (VanBogelen 
and Neidhardt, 1990). In conclusion, it is difficult to correlate stress responses 
related to antibiotics with their effects on the ∆ssrA strain. 
Recently, two proteins ArfA and YaeJ, have been described to be able to 
rescue stalled ribosomes independently from tmRNA (Chadani et al., 2010, 
Chadani et al., 2011). It is possible that those proteins can rescue stalled 
ribosomal complexes induced by some antibiotics but not by others. The 
antibiotic sensitivity pattern of the ∆ssrA strain might be the result of the ability 
of ArfA and YaeJ to compensate for the lack of tmRNA. Validating this 
hypothesis would need further testing. 
 
2.2.2. Bactericidal activity 
Since the ability to cause cell death is an important parameter of antibiotics, we 
measured the bacterial viability in the presence of drugs which previously 
showed differeces in the activity against the ∆ssrA and wild type strains. We 
wanted to test whether bactericidal antibiotics are more effective against the 
∆ssrA strain or do bacteriostatic drugs start to behave bactericidally. We also 
included norfloxacin as the representative of bactericidal fluoroquinolones. The 
concentrations used were chosen such that caused in both strain a complete or 
maximum inhibition of growth. 
The biggest difference in the killing efficiency between the wild type and 
∆ssrA strain was observed for kanamycin and streptomycin (I, Fig. 3). A drop 
of CFUs, less than an order of magnitude, of the ∆ssrA strain was specific also 
for the bacteriostatic erythromycin. Other bacteriostatic ribosome targeting 
drugs did not show any significant differences between the wild type and ∆ssrA 
strain. 
Norfloxacin, ampicillin and fosfomycin did not act differently on the test 
strains (I, Fig. 4). As the initially chosen concentration was killing very quickly, 
and we were afraid that the killing is too rapid to observe the differences, we 
also used two lower concentrations. The lowest concentration was chosen to 
cause only growth inhibition, while the third caused only slow killing. 
Deletion of the ssrA caused the most prominent sensitization effect against 
aminoglycosides. The tmRNA defective strain showed a significant growth 
defect and was more prone to be killed by kanamycin and streptomycin. Those 
effects can be explained at the molecular level. It has been reported that even 
low concentrations of aminoglycosides are inducing global SsrA tagging (Abo 
et al., 2002). Aminoglycosides cause misreading of the mRNA during protein 
synthesis, which can be realized by over reading of the stop codon or 
frameshifting, and can lead to ribosome stalling on the 3’ end of the mRNA. 
The SsrA-specific tagging could be the result of tmRNA activity releasing 
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ribosomes stalled on the 3’ ends of the mRNAs. The growth defect caused by 
destruction of trans-translational machinery could arise from the reduced pool 
of free ribosomes. 
In addition to releasing the ribosomes, tmRNA directs proteins, 
mistranslated by the ribosomes that reach the 3’ end of the mRNA, into 
degradation. Those proteins are potentially toxic as they contain an additional 
C-terminal sequence that might hinder proper folding of the proteins and they 
could mislocalize, through exposed hydrophobic regions, into membranes. At 
the same time, an important factor for bactericidal activity of aminoglycosides 
is thought to be the accumulation of mistranslated proteins in membranes, 
resulting in the loss of membrane potential. The stronger bactericidal effect of 
aminoglycosides against the ∆ssrA strain could result from the increased 
accumulation of misfolded proteins in the membranes. This hypothesis would 
be interesting to test with the mutant strain coding for the protease resistant 
SsrA-tag to see if the accumulation of mistranslated proteins, by itself, is 
capable to induce cell death at lower concentrations of aminoglycosides. 
The quest for novel compounds enhancing the effectiveness of current drugs 
has got off the ground during the last decade. We conclude, based on the current 
results, that tmRNA could be a potential target for those novel drugs, to 
potentiate several ribosome targeting drugs and cell wall inhibitors. Especially 
interesting would be the potentiation of aminoglycosides as their bactericidal 
activity is also enhanced. Another aspect about aminoglycosides is that, due to 
the toxicity issues, their use is restricted (Hermann, 2007). Potentiating their 
effectiveness would be specific only for bacteria allowing the use of lower 
concentrations and thereafter increase their usage in clinical practice, due to the 
decrease of toxicity. 
 
 
2.3. Heterogeneity of stationary phase cultures and  
its impact on the frequency of persisters (II, III) 
Most of the studies in the field of bacteriology have been conducted on the 
whole population level so that parameters have been measured as an average of 
the population. This kind of approaches will fail to take heterogeneity into 
consideration, although it is acknowledged as an important aspect of various 
processes, including the ones taking place in stationary phase cultures (Cormack 
et al., 1996). 
The studies on heterogeneity have so far been somewhat limited due to the 
technical aspects of many methodologies that often do not allow describing the 
processes at the single cell level. This limitation can be overcome by 
microscopy, specifically live-cell imaging, which enables us to follow growth, 
death and responses to the environment of the single cells (Stewart et al., 2005, 
Balaban et al., 2004). However, live-cell imaging has its own limitations. It can 
be time consuming and often subjective if special software is not used. In 
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addition, the number of cells analyzed per experiment can be rather small, 
making the statistical analysis complicated or even impossible. Also, the 
physical isolation/collection of specific cells or a subpopulation can be 
complicated if not possible at all. Those limitations can be at least partially 
overcome using high-throughput microscopy, but this equipment might not be 
available in every facility (Pepperkok and Ellenberg, 2006). 
 
2.3.1. Tool for studying heterogeneity at the single cell level 
Flow cytometry can be used for measurements of a large number of cells almost 
simultaneously at the single cell level with a low cost. In addition, flow 
cytometer is a relatively common piece of equipment. Moreover, single cells or 
certain subpopulations can be isolated via fluorescence activated cell sorting 
(FACS). Those were the reasons that lead us to the development of a flow 
cytometric assay that is relying on the dilution of fluorescent proteins (II,  
Fig. 1). 
The principle of the assay is based on the stepwise dilution of the marker 
protein (in the current study the green fluorescent protein (GFP)) (II, Fig. 1). 
GFP-labeled cells, dividing at a similar rate, will form a single peak, decreasing 
in intensity over time on the histogram of fluorescent intensity. In case of the 
non-dividing cells, the intensity of the peak will stay the same. Heterogeneous 
population, on the other hand, would result in a more complicated histogram, 
for example, the mixture of non-dividing and dividing cells would generate two 
peaks. 
We used the stable isoform of GFP (GFPmut2) (Cormack et al., 1996) which 
is not degraded during the timeframe of our experiments. Similar expression 
systems have shown that this protein is accumulating in large amounts, and it is 
freely diffusing in the cytoplasm (van den Bogaart et al., 2007, Mullineaux et 
al., 2006, Elowitz et al., 1999). This means that after the removal of the 
inductor, the weakening of the signal is reporting the cell division, not affected 
by the stochastic dilution process, which could be the case when only a few 
molecules are present in the cell (Shapiro, 2003). Similarly, the process is not 
affected by protein degradation or aggregation.  
 
2.3.2. Cell division in different growth phases 
First experiments to test the method were to analyze the cell divisions of E. coli 
in different growth phases at the single cell level (II, Fig. 2). For this purpose 
the cells were labeled with GFP by the addition of the inducer. Before starting 
to collect samples for flow cytometric analysis, the inducer was removed by 
diluting the culture into fresh media (exponential phase culture) or the medium 
was replaced by conditioned medium, devoid of the inducer (other growth 
phases). 
44 
 
As expected, the cells in the exponential phase culture were dividing in a 
uniform manner as the reduction of GFP intensity was continuous over the 
whole population (II, Fig. 2A). From the reduction rate of the fluorescence 
intensities during the first time points we calculated the doubling time, which 
was approximately 25 minutes. This is in correlation with the doubling time of 
exponential phase culture measured by optical densities (data not shown). In the 
later time points the fluorescent intensities started to reach the basal level, and 
therefore the quantitative relationship between growth rate and GFP dilution 
was lost. 
Generally, the stationary phase of bacterial culture has been thought to be a 
stage where growth of the cells is halted. This is concluded from the fact that 
CFUs per milliliter of the stationary phase culture and also the cell number, 
measured microscopically, do not change. It is also possible that in the 
stationary phase there is a balance between cell death and cell division, 
therefore keeping the cell numbers constant. So far, there was no direct method 
to confirm either of these hypotheses. In addition, it was not known whether all 
the cells enter the stationary phase at the same time, in other words, do all the 
cells stop growth at the same time or is it distributed in time.  
Our assay enabled to address those questions. We saw that the cells, 
prelabeled with GFP, entered the non-dividing state (stationary phase) in a 
uniform manner as the GFP dilution slows down and stops, without changing 
the shape of the peak of the fluorescence intensity in the histogram (II, Fig. 2B). 
Similar experiment was repeated with the cells from deeper stationary phase. 
We did not see any reduction in GFP intensities, meaning that at least E. coli is 
in stationary phase, for a certain timeframe, in a non-proliferating state.  
 
2.3.3. Heterogeneity upon recovery from stationary phase 
Persisters are a very small subpopulation (commonly referred to as 1:10 000 – 
1:100 000) of cells, known to originate mostly from stationary phase as cells 
which after dilution into fresh medium recover slower and therefore are 
insensitive to the bactericidal drugs (Lewis, 2010). We were interested to see 
whether our assay is sensitive enough to observe the population of non-
proliferating cells after the dilution into a fresh media. To achieve this, we kept 
cells, prelabeled with GFP, for 24 hours in the stationary phase in LB medium 
and then diluted them into fresh medium. For our surprise, only a small fraction 
of cells started to divide, as their GFP intensity started to decrease (II, Fig. 3A). 
The rest of the cells retained high GFP content, meaning that they stayed 
dormant. As the number of cells with intermediate fluorescence remained very 
low we can say that the number of cells resuming growth later was low. 
As the frequency of non-dividing cells was much higher than the commonly 
measured persister frequency we were interested to know what is behind this 
difference. It is likely that during the stationary phase, some cells have lost the 
viability but do not lyze and are measured as non-dividing cells in our assay. To 
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test this, we used propidium iodide staining, commonly used to differentiate 
dead cells from the living cells (Pin and Baranyi, 2008). We saw that an only 
small fraction of the whole population (both non-dividing and dividing cells) 
had lost their membrane integrity (II, Fig. 4). From these data we conclude that 
probably the massive cell death is not behind the differentiation into non-
dividing and dividing subpopulations.  
 
2.3.4. Persisters and the age of inoculum 
As the high number of cells, unable to recover from stationary phase, was 
probably not a result of cell death, we decided to go more into the detail and 
measure the persister frequency in the same conditions (in LB medium, using 
inoculum from 24 hours old stationary phase culture). Using ampicillin and the 
plating method we determined the persister frequency to be about 10% (data not 
shown), which is much higher than commonly reported (Moyed & Bertrand, 
1983, Keren et al., 2004a). 
It is known that during the stationary phase the cells are losing viability 
(Siegele et al., 1993, Desnues et al., 2003) and also the delay of growth 
resumption, upon dilution into fresh media, has been observed (Pin and 
Baranyi, 2008). At the same time, in the reports where persister frequencies 
have been measured the inoculum has been originating from 12–15 hours old 
cultures (Gefen et al., 2008, Balaban et al., 2004) or not much attention was 
paid to the age of the inoculum. In the latter case usually only the use of the 
overnight culture is referred (Keren et al., 2004a, Dorr et al., 2010). Most 
probably, the overnight culture would mean the length of the stationary phase 
about 12–16 hours, which is shorter than the stationary phase studied by us. We 
thought that observed high frequency of non-dividing and persister cells might 
be linked to the changes in the cultivability during the stationary phase. From 
this, we decided to measure the dependence of persister frequency on the length 
of the stationary phase. 
We measured the dependence of the persister frequency on the age of 
inoculum, both in LB (rich medium) and in a MOPS medium supplemented 
with glucose (minimal medium) (III, Fig. 1). Interestingly, in both media we 
saw a drastic change in persister frequency as the inoculum aged. When the 
inoculum was taken from a short stationary phase culture, the observed persister 
frequencies were in the range of commonly reported values 10–4–10–6 (Moyed 
& Bertrand, 1983, Keren et al., 2004a), but as the inoculum got older, the 
persister frequency started to increase and reached up to 10% of the total 
number of cells. It is noteworthy that in the LB medium the persister frequency 
increased in the matter of hours, but in the MOPS medium it took longer time 
and the time frame was measured in days.  
We have demonstrated that GFP-labeled cells, which do not start to divide 
upon dilution into the fresh media, are insensitive to ampicillin, as they are not 
lyzed and are easily detectable by the high retained fluorescence (II, Fig. 6). 
12
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Therefore, we were able to follow also the number of non-dividing cells in the 
very same experiment with persister frequency determination. We noticed that 
the number of unlyzed cells at the end of the antibiotic treatment (at the moment 
of plating a sample of culture to determine the frequency of survivors 
(persisters)) shared the pattern with the persister frequency – in case the short 
stationary phase was used for inoculation, their level was low but increased as 
the inoculum aged (III, Fig. 1). The change was not identical, as the ratio of 
persisters to non-dividing cells changed. For example, in LB, the ratio was 
initially < 1:1 000 and increased up to 1:10 and it started to decrease again when 
inoculum from the older stationary phase culture was used. 
Those experiments illustrate the fact that not all dormant cells, surviving the 
ampicillin treatment, are persisters, contrary to previous beliefs (Shah et al., 
2006, Kussell & Leibler, 2005, Keren et al., 2004b). In these previous studies, 
the unlyzed or dormant cells were collected, and their gene expression profiles 
were analyzed. From these data the generalization for persister cells was made. 
In the light of current results, we can say that the gene expression profiles, 
analyzed earlier, describe all dormant cells not able to start growth upon 
dilution into the fresh medium and the persisters were forming only a small 
fraction from those cells. A more appropriate approach would have been to 
comparing the profiles of cells collected after different lengths of antibiotic 
treatment. The differences between consecutive profiles would have reflected 
the cells that had started to divide and lyzed in between collecting two 
consecutive samples – the cells that do fulfill the definition of persisters. 
The inoculum’s age-dependent increase of persister frequency, surviving the 
3 hour long ampicillin treatment, could manifest itself in terms of delay in the 
growth resumption. Indeed, a closer look at the dynamics of the growth 
resumption reveals the delay. The longer the stationary phase, the longer time it 
takes for the cells to start growth (III, Fig. 2), a phenomenon seen also before 
(Pin and Baranyi, 2008).  
Those are the first experiments reporting the high persister frequency of the 
wild type E. coli in growing culture. In fact, the persister frequency is 
comparable to the classical high persister strain hipA7 (Keren et al., 2004a, Dorr 
et al., 2010). Therefore, we were interested to measure the persister levels of 
hipA7 in our assay. For the hipA7 strain we observed a dynamic persister profile 
when different inocula were used (III, Fig. 1). In case the inoculum originated 
from the short stationary phase the persister frequency was higher as compared 
to the wild type strain. The persister frequency was in the range reported before 
(Keren et al., 2004a, Dorr et al., 2010). As the inoculum aged, the persister 
frequency increased, but at lower rate as compared to the wild type strain, 
leading to the similar persister levels of the both strains when aged inocula were 
used. 
Quite often the hipA7 strain has been used as a model to study the persister 
phenomenon as it has high persister frequency which is making the collection of 
material and data, or measuring persister levels easier. On the other hand, hipA7 
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is a mutant strain and it is not completely clear how the higher persister rate is 
achieved. In addition, we do not exactly know how the mutations behind the 
hipA7 strain influence the physiology of the cell and can it have an impact on 
the results obtained using this strain. One difference, compared to the wild type 
strain is known – the hipA7 strain is cold sensitive (Scherrer and Moyed, 1988), 
although it could directly be linked to the binding kinetics of HipA and HipB 
proteins (Rotem et al., 2010). Therefore, the use of the wild type strain for 
studying the persister phenomenon would be more appropriate. As we have now 
revealed the conditions where the persister level of the wild type strain is much 
higher than previously observed, the use of wild type strain could be prevail 
more. 
This kind of persister dynamic has not been observed before. As already 
mentioned, the commonly used inoculum in the persister assays has probably 
spent in stationary phase about 12–16 hours. In our assay, the inoculum that has 
spent similar time in stationary phase in LB medium is showing the similar 
persister frequencies for the wild type and hipA7 cultures (III, Fig. 1). One 
difference in our setup, compared to the previous reports, is GFP labeling that 
we are using for observing the growth resumption. Even without the induction 
of GFP expression (III, Fig. S1) or using a strain not carrying plasmid for GFP 
expression, we observed similar results (III, Fig. 4). The second important 
difference is the use of filter-sterilized LB medium. We noticed that using 
autoclaved LB medium the growth resumption results were not reproducible. 
We often observed that, after the 24 hour long stationary phase, nearly all cells 
were able to resume growth upon dilution into fresh medium (data not shown). 
After we started to use the filter-sterilized medium, the reproducibility issues 
were gone. A possible reason for the observed phenomenon is that the 
autoclaving can change the composition of the medium (Padgett and Leonard, 
1994; Wang and Hsiao, 1995), resulting in the changes of the growth supporting 
properties of the medium (Field and Lichstein, 1958; Pedrotti et al., 1994). The 
chemical changes can depend on several factors, including the volume of the 
material and type of the autoclave (Wang & Hsiao, 1995, Cook et al., 1989), 
which we probably were not able to control. So it seems that the chemical 
composition of the LB medium can change processes taking place during the 
stationary phase in LB and are changing the cultivability of the cells. This 
would mean that the previous studies were conducted using media where 
cultivability of the cells did not decrease so fast as in our LB medium. With 
regard to the MOPS medium, the previously unnoticed high persister 
frequencies of wild type E. coli can be explained by the fact that nobody had 
previously used inocula from the stationary phase culture as old as we were 
using to perform the persister assay. 
The growth resumption dynamic of the hipA7 strain was very similar to the 
wild type strain (data not shown). This is conflicting with the previous 
observation (Balaban et al., 2004) that the hipA7 strain has a higher level of 
cells recovering slowly from dormancy as compared to wild type. As the growth 
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conditions (microfluidic device versus batch culture) and cell detection method 
(microscopy versus flow cytometry) are different the results might not be 
directly comparable. However, in accordance with the previous results, hipA7 
differed from the wild type in the high persister level in case the inoculum was 
taken from the early stationary phase (III, Fig. 1). 
To test, is the observed dependence of the persister frequency on the age of 
the inoculum specific to ampicillin or is it common to all bactericidal drugs, we 
conducted the persister assays using other types of bactericidal drugs (III, Fig. 
3). Persister frequencies in response to norfloxacin treatment, a representative 
of fluoroquinolones, were quite similar to the results with ampicillin. On the 
other hand, amikacin (belongs to the class of aminoglycosides) killed all cells 
irrespective of inoculum age. This is in correlation with previous reports 
showing that treatment with aminoglycosides can lead to a very low level of 
persisters or even sterilization of the cultures (Zuroff et al., 2010, Wiuff et al., 
2005, Spoering & Lewis, 2001). The effect of aminoglycosides raises an 
interesting possibility that the persisters could synthesize proteins. This is in 
correlation with previous work from Gefen and coworkers, where they observed 
that a small subpopulation of cells, resuming growth later as compared to the 
majority of the cells, was able to synthesize proteins during the small timeframe 
upon dilution into a fresh medium (Gefen et al., 2008). In addition, it has been 
demonstrated that certain metabolites, presumably also present in fresh LB 
medium, can promote proton motive force, possibly also in persister cells, that 
facilitates aminoglycoside uptake, which could result in cell death (Allison et 
al., 2011). 
The explanation for the changes of the growth resumption and persister 
levels could be the ageing of the cells during stationary phase. As previously 
mentioned, it has been reported that during stationary phase, cells can 
accumulate damages that can be reflected in carbonylation of proteins as an 
example of oxidative damage. When cells are damaged the growth resumptions 
could be affected as the repair of their constituents may take additional time. 
Desnues and colleagues reported bimodal distribution of oxidatively damaged 
proteins among stationary phase cells. The higher degree of accumulated 
damage was associated with lower cultivability (Desnues et al., 2003). This 
could be a reason behind the increasing number of cells with slow growth 
resumption ability. 
In contrast to the ageing theory, the changes we observed in the behavior of 
the cells could also be explained by the bet-hedging theory, generating 
phenotypic heterogeneity under uncertain conditions (Beaumont et al., 2009). It 
is possible that the expectations for the forthcoming conditions are changing 
during the stationary phase. Therefore, overall changes in the growth 
resumption ability, including formation of the cells resuming growth slowly, 
might be a tightly controlled process and might reflect the higher expectation of 
longer famine period or catastrophic events. Those explanations do not have to 
be mutually exclusive as the controlled formation of the dormant cells could 
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take advantage of the changed cultivability caused by the accumulation of 
damages. 
2.3.5. Genes related to persistence 
In addition to hipA7, there are also several deletion mutants which have 
changed the persister frequency (Spoering et al., 2006, Scherrer & Moyed, 
1988, Ma et al., 2010, Li & Zhang, 2007, Kim & Wood, 2010, Hansen et al., 
2008, Dorr et al., 2010, Dorr et al., 2009, Aizenman et al., 1996). Interestingly, 
the lists of the genes identified do not overlap and in the light of the current 
results the influence of the experimental conditions seems likely to be the cause. 
To test this hypothesis we chose 1–3 strains, which showed strongest reduction 
in persister levels, from each report and tested their persister levels in the 
conditions of the ageing inocula. As several previous screens (Ma et al., 2010, 
Hansen et al., 2008) were conducted with the Keio collection (Baba et al., 
2006), we initially decided to use also the Keio strains. It turned out that, in our 
assay conditions, several selected strains did not differ from the wild type strain 
at all (III Fig. S3). It did not escape our attention that those strains might have 
acquired secondary compensatory mutations and kanamycin resistance cassette, 
used to replace the target gene, could cause polar effects. On this basis, we 
constructed most of the strains anew (exception was sucB that we were not able 
to delete in a clean background) and removed the antibiotic resistance cassette. 
Indeed, there were slight changes in persister frequencies compared with the 
strains originating from the Keio collection (III, Fig. 4).  
We identified various effects of the age of inoculum on the knockout strains 
and they fall into three groups. The first contains mqsR (toxin from a TA 
system) (Kim & Wood, 2010) and phoU (regulator of phosphate metabolism) 
(Li and Zhang, 2007) knockout strains, and they were behaving similar to the 
wild type, when the inoculum was taken from a younger stationary phase, but in 
case of the later time points the persister levels were more than an order of 
magnitude lower. 
The second group contained glpD (enzyme in cental metabolism) (Spoering 
et al., 2006), surA (peptidyl-prolyl cis-trans isomerase) (Hansen et al., 2008) 
and dnaJ (chaperon) (Hansen et al., 2008) knockout strains that had a lower 
level of persisters when the inoculum originated from the early-stationary phase 
cultures. In the last time point, their persister level exceeded the wild type 
levels.  
The third group is formed by sucB (enzyme in TCA cycle) (Ma et al., 2010), 
ygfA (enzyme in folate biosynthesis) (Hansen et al., 2008) and recA (DNA 
recombination protein) (Dorr et al., 2009) knockout strains, as they showed a 
lower persister levels in every time point examined. It is important to note that 
the recA deletion strain had strong growth defects (data not shown); therefore 
the relevance of this strain in the context of the current work is questionable. 
Interestingly, the effect of the sucB deletion was considerably larger and 
therefore gained more attention from us. We asked what could be behind the 
13
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low persister phenotype. It can be achieved by very fast growth resumption that 
is accompanied by the low fraction of slowly recovering cells. Another 
possibility is that the cells, which survived the antibiotic treatment, did not 
survive the plating and are causing low CFU read. To test those hypotheses, we 
measured the persister frequencies and growth resumption in parallel (III, Fig. 
5). Indeed, growth resumption of the sucB deletion strain was much faster as 
compared to wild type, and it was not significantly delayed or slowed down 
during the ageing of the inoculum.  
The phenotype of the sucB knockout strain could be the result of the growth 
dynamics of the culture, as the maximum optical density during stationary 
phase is about 1/3 of the wild type (data not shown). This suggests that the sucB 
knockout strain does not use all the resources before entering into stationary 
phase. This assumption is supported by the preliminary results, showing that the 
wild type strain can resume growth in the stationary phase media of sucB 
mutant (data not shown). The ability of the sucB mutant to resume growth 
rapidly, upon dilution into the fresh medium, indicates that it could be in a 
relatively active state during the stationary phase, subsidized by the remaining 
resources. Therefore, the strain might not be properly prepared for the stationary 
phase, in the sense of feast and famine conditions. Indeed, this assumption is 
supported by the preliminary experiments, showing that sucB mutant is rapidly 
losing its viability in the spent stationary phase media of the wild type strain 
(data not shown). This trade-off might explain why wild type cells do not have 
acquired the sucB knockout-like properties of the rapid growth resumption, 
which could be an advantage after entry into the growth supporting conditions.  
sucB codes for an enzyme, involved in the tricarboxylic acid cycle. Several 
other enzymes from the same pathway have previously been shown to be 
involved in modulating the antibiotic action (Kohanski et al., 2007). Therefore, 
we measured persister levels of the deletion strains of icdA, mdh and acnB (III, 
Fig. 6). Phenotype of acnB deletion was most similar to the sucB mutant with 
the low persister level. However, in the last time point the persister level 
increased and was comparable with the wild type. The persister levels of other 
deletion strains (mdh, icdA) were exceeding wild type at the first time point but 
were merging with the level of wild type later, resembling the phenotype of the 
hipA7 strain (III, Fig. 1). This demonstrates that central metabolism can change 
the persister levels, although explaining the effect of particular genes requires 
further experimentation.  
The patterns in the persister levels of the mutant strains give rise to a 
hypothesis that the difference in the persister levels, between the wild type and 
several knock-out strains, may arise from the changed speed of the formation of 
persisters during the ageing of the stationary phase. For example, this process 
seemed to have accelerated for mqsR and phoU mutants (III, Fig. 4 B, D), but 
delayed for the deletion strains of glpD, surA, dnaJ (III, Fig. 4 A, C and E) and 
acnB (III, Fig. 6) when compared with the wild type. Moreover, in the case of 
the wild type strain the persister levels are changing hand-in-hand with growth 
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resumption. This suggests that perhaps, in those mutant strains, the changed 
dynamics of the persisters is accompanied also with the delay or acceleration of 
growth resumption. To validate this hypothesis further, measuring of the growth 
resumption kinetics, together with the gene expression and/or proteome 
analysis, is needed to compare the wild type and mutant strains. Another out-
standing mutant is the ygfA deletion strain (III, Fig. 4 F), as its persister 
dynamic is following the dynamics of the wild type (the persister levels did 
increase and decrease in the same rhythm), although it was lower in every time 
point. It would be interesting to see in what extent is the growth resumption of 
the affected ygfA deletion strain, and how it relates to the changes in persister 
levels. 
In conclusion, I can say that we have developed a method, enabling to 
observe heterogeneity in bacterial cultures based on the growth differences. 
This method can be and already is adapted to other organisms and experimental 
systems to study heterogeneity (Helaine et al., 2010). In addition, I have 
demonstrated various dynamic profiles in the persister frequencies that are 
influenced by the growth conditions, history of inoculum and genotype of the 
strain. 
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CONCLUSIONS 
 Deficiency of trans-translation system increases susceptibility of E. coli 
to several ribosomal targeting antibiotics and inhibitors of the cell wall 
synthesis, and enhances the bactericidal activity of aminoglycosides. 
 The flow cytometric assay was developed to follow cell division at 
single cell level. Using this assay, it was demonstrated that E. coli is 
dividing uniformly through different growth stages and during 
stationary phase is in a non-proliferating state 
 Persisters are forming only a small fraction from all non-dividing cells. 
 The frequency of persisters depends on the inoculum, particularly on its 
age and the medium composition. As the stationary phase culture is 
ageing, the ability of the cells to resume growth upon dilution into fresh 
media is changing: growth resumption delays as the rate of growth 
resumption goes down and the number of cells resuming growth in a 
slower rate is increasing, which results higher frequency of persisters. 
In rich medium, these processes are much faster compared to the 
minimal medium.  
 The persister levels of various mutants were differentially influenced by 
the age of the inoculum underlining great importance of the 
experimental details during the screening for altered persistence.  
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SUMMARY IN ESTONIAN 
Escherichia coli antibiootikumitundlikkust  
mõjutavad tegurid 
Antibiootikumid on ühendid, mis tugevalt pärsivad mikroobide kasvu või 
surmavad neid. Esimeste antibiootikumide kasutusele võtmise ajal arvati, et 
need ravimid vabastavad inimkonna jäädavalt ohtlikest ning tihti surmaga 
lõppevatest nakkushaigustest. Peatselt hakkasid aga ilmuma teated resis-
tentsetest bakteritüvedest, mis laialdase leviku tõttu muutsid paljud antibiooti-
kumid kasutuks. Siiski avastati või sünteesiti esialgu pidevalt juurde mitmeid 
uusi antibakteriaalseid ühendeid, mis aitasid hoida resistentsete tüvede leviku 
kontrolli all. Peagi aga langes uute antibiootikumide turule tuleku tempo üsna 
märgatavalt ning nüüdseks on resistentsed tüved üle maailma tõsiseks 
probleemiks ja harvad ei ole juhud, kus ka nö. reservravimid on kasutud. See-
tõttu on viimasel ajal otsitud viise, kuidas olemasolevate antibiootikumide 
toimet võimendada.  
Korduvalt on näidatud, et antibiootikumidel on laialdane mõju bakteri füsio-
loogiale. Seetõttu on ühe võimalusena antibiootikumide mõju võimendamiseks 
otsitud lisaks otsesele sihtmärgile ka teisi protsesse, mille paralleelne inhi-
beerimine võiks tuua kaasa suurema antibiootikumi tundlikkuse. Üheks selli-
seks protsessiks on osutunud trans-translatsioon, mida viib läbi tmRNA ning 
mis seisneb mRNA-le kinnijäänud ribosoomide vabastamises.  
Varem on tmRNA-d kodeeriva geeni eemaldamise mõju vaadeldud ainult 
valgusünteesi inhibeerivate antibiootikumide korral (Vioque & de la Cruz, 
2003, de la Cruz & Vioque, 2001, Athamna et al., 2004, Abo et al., 2002). Kuna 
tmRNA mõjutab mitmeid erinevaid rakulisi protsesse, otsustasime uurida, kas 
vigase trans-translatsiooni süsteemiga Escherichia coli on tundlikum ka teiste 
sihtmärkidega antibiootikumide suhtes. Me testisime laia valikut erinevaid 
antibiootikume ning leidsime, et lisaks mitmetele valgusünteesi inhibeerivatele 
antibiootikumidele muutis tmRNA puudumine E. coli tundlikumaks ka raku-
kesta sünteesi inhibiitoritele. Lisaks kasvuinhibitsiooni mõõtmisele võrdlesime 
ka tapmise efektiivsust. Me leidsime, et ainult aminoglükosiidid, mis on 
valgusünteesi inhibiitorid, surmasid tmRNA puudulikku tüve tunduvalt efek-
tiivsemalt kui metsiktüüpi tüve. Sellest me järeldasime, et tmRNA ja trans-
translatsioon võiksid olla sihtmärk, et võimendada mitmete valgusünteesi 
inhibiitorite (eriti aminoglükosiidide) ning rakukestasünteesi inhibiitorite 
toimet. 
Kõik seniuuritud bakteripopulatsioonid sisaldavad väikest hulka antibiooti-
kumidele tundetuid baktereid, mida kutsutakse persistoriteks. Selle nähtuse 
puhul ei ole siiski tegemist resistentsusega, kuna persistorid on geneetiliselt 
idententsed ülejäänutega, mis tähendab, et tegemist on hoopis fenotüübilise 
muutlikkuse nähtusega. Kuna persistoreid peetakse krooniliste ja pikaajaliste 
infektsioonide põhjustajaks, siis nende hulga vähendamine võiks samuti aidata 
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muuta raviskeeme praeguste antibiootikumide puhul efektiivsemaks. Siiski on 
persistorite fenomeni olemus, hoolimata enam kui 60 aasta tagusest esma-
kirjeldusest, suurel määral selgusetu. Seetõttu keskendusin doktoritöö teises 
osas persistorite teket mõjutavate faktorite uurimisele. 
Persitorite kohta on teada, et nad on madala metaboolse aktiivusega nn. 
uinunud olekus olevad bakterid (Lewis, 2010). Samas on selliste bakterite hulk 
populatisoonis väga madal, mistõttu on olnud neid seniste meetoditega üsna 
keeruline lähemalt uurida. Sellest probleemist ülesaamiseks töötasime välja 
bakterirakkude jagunemise jälgimiseks uudse meetodi, mis põhineb fluo-
restseeruva valgu lahjenemisel. Kuna rakkude detektsioon toimub voolutsüto-
meetri abil, siis on selle meetodi abil võimalik kiirelt mõõta paljude rakkude 
parameetreid. See lubab tuvastada ka väikest hulka mittejagunevaid rakke. 
Järgnevalt tuvastasime, et peale pikemat statsionaarset faasi muutus rakkude 
kasvama hakkamise võime nii, et järjest rohkem tekkis mittejagunevaid rakke ja 
üldine kasvama hakkamine hilines. Persistorite hulk järgis seejuures mitte-
kasvavate rakkude dünaamikat. Kokkuvõtvalt võib öelda, et persistorite tase 
sõltub olulisel määral inokulumi ajaloost, eriti just vanusest ning ka 
kasvatamiseks kasutatud söötmest.  
Persistoreid põhjustavate mehhanismide otsingul on tuvastatud mitmeid 
geene, mille eemaldamine vähendab persistorite hulka. Siiski ei kattu erinevates 
uuringutes tuvastatud geenide nimekirjad sageli omavahel. Me näitasime, et 
põhjuseks võivad olla erinevused katsetingimustes. Näiteks võib mutandi 
persistorite tase erineda metsiktüüpi tüvest ainult teatud inokulumi vanuse 
korral. 
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